WO2023080895A1 - Traitement du cancer avec des cellules nk et des agents de mise en contact multispécifiques - Google Patents
Traitement du cancer avec des cellules nk et des agents de mise en contact multispécifiques Download PDFInfo
- Publication number
- WO2023080895A1 WO2023080895A1 PCT/US2021/058136 US2021058136W WO2023080895A1 WO 2023080895 A1 WO2023080895 A1 WO 2023080895A1 US 2021058136 W US2021058136 W US 2021058136W WO 2023080895 A1 WO2023080895 A1 WO 2023080895A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- seq
- cell
- complementarity determining
- pharmaceutical composition
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 256
- 206010028980 Neoplasm Diseases 0.000 title claims description 76
- 201000011510 cancer Diseases 0.000 title claims description 58
- 238000011282 treatment Methods 0.000 title description 33
- 238000000034 method Methods 0.000 claims abstract description 80
- 239000000427 antigen Substances 0.000 claims abstract description 73
- 102000036639 antigens Human genes 0.000 claims abstract description 73
- 108091007433 antigens Proteins 0.000 claims abstract description 73
- 239000012634 fragment Substances 0.000 claims abstract description 60
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 58
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims abstract description 44
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims abstract description 43
- 102000054766 genetic haplotypes Human genes 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 357
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 72
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 67
- 210000004700 fetal blood Anatomy 0.000 claims description 59
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 52
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 52
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 39
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 33
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 101100334515 Homo sapiens FCGR3A gene Proteins 0.000 claims description 19
- 108010002350 Interleukin-2 Proteins 0.000 claims description 19
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 18
- 239000012528 membrane Substances 0.000 claims description 16
- 238000012258 culturing Methods 0.000 claims description 12
- 125000000539 amino acid group Chemical group 0.000 claims description 11
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 9
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 9
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 8
- 108700026220 vif Genes Proteins 0.000 claims description 8
- 108010073807 IgG Receptors Proteins 0.000 claims description 7
- 230000000779 depleting effect Effects 0.000 claims description 7
- 229940127174 UCHT1 Drugs 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 abstract description 9
- 239000001963 growth medium Substances 0.000 description 92
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 62
- 238000013411 master cell bank Methods 0.000 description 48
- 201000010099 disease Diseases 0.000 description 33
- 241000282414 Homo sapiens Species 0.000 description 32
- 208000035475 disorder Diseases 0.000 description 29
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 26
- 239000000203 mixture Substances 0.000 description 26
- 238000003501 co-culture Methods 0.000 description 24
- 229940126534 drug product Drugs 0.000 description 24
- 239000000825 pharmaceutical preparation Substances 0.000 description 24
- 102000004196 processed proteins & peptides Human genes 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 238000005138 cryopreservation Methods 0.000 description 18
- 229920001184 polypeptide Polymers 0.000 description 18
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 15
- 150000007523 nucleic acids Chemical group 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- 108091006905 Human Serum Albumin Proteins 0.000 description 14
- 102000008100 Human Serum Albumin Human genes 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 102000009027 Albumins Human genes 0.000 description 13
- 108010088751 Albumins Proteins 0.000 description 13
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 13
- 235000004554 glutamine Nutrition 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 108010043610 KIR Receptors Proteins 0.000 description 11
- 102000002698 KIR Receptors Human genes 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 11
- 238000010257 thawing Methods 0.000 description 11
- 102100033458 26S proteasome non-ATPase regulatory subunit 4 Human genes 0.000 description 10
- 201000009030 Carcinoma Diseases 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 101150001079 PSMD4 gene Proteins 0.000 description 10
- 101150006293 Rpn10 gene Proteins 0.000 description 10
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- -1 IL- 18 Proteins 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 230000002062 proliferating effect Effects 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 102000003812 Interleukin-15 Human genes 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 229960002378 oftasceine Drugs 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 6
- 108091008877 NK cell receptors Proteins 0.000 description 6
- 102000010648 Natural Killer Cell Receptors Human genes 0.000 description 6
- 108010042215 OX40 Ligand Proteins 0.000 description 6
- 101710160107 Outer membrane protein A Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 241000283984 Rodentia Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 229920001993 poloxamer 188 Polymers 0.000 description 6
- 229940044519 poloxamer 188 Drugs 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 206010039491 Sarcoma Diseases 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 230000006037 cell lysis Effects 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 229960000390 fludarabine Drugs 0.000 description 5
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 5
- 239000012595 freezing medium Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000710 homodimer Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 201000005962 mycosis fungoides Diseases 0.000 description 5
- 230000001613 neoplastic effect Effects 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 229940054269 sodium pyruvate Drugs 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 4
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 230000003463 hyperproliferative effect Effects 0.000 description 4
- 239000013067 intermediate product Substances 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 101100334524 Homo sapiens FCGR3B gene Proteins 0.000 description 3
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 101001024425 Mus musculus Ig gamma-2A chain C region secreted form Proteins 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 230000006051 NK cell activation Effects 0.000 description 3
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 3
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 3
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 3
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000009702 cancer cell proliferation Effects 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 3
- 206010052015 cytokine release syndrome Diseases 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 201000009277 hairy cell leukemia Diseases 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 239000011325 microbead Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 3
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000021309 Germ cell tumor Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000945335 Homo sapiens Killer cell immunoglobulin-like receptor 2DL5B Proteins 0.000 description 2
- 101000945339 Homo sapiens Killer cell immunoglobulin-like receptor 2DS2 Proteins 0.000 description 2
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 2
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 206010061252 Intraocular melanoma Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 102100033628 Killer cell immunoglobulin-like receptor 2DL5B Human genes 0.000 description 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 2
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 2
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 2
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 2
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 2
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 201000005969 Uveal melanoma Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000009175 antibody therapy Methods 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 229940119744 dextran 40 Drugs 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 238000010228 ex vivo assay Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 208000024348 heart neoplasm Diseases 0.000 description 2
- 201000006866 hypopharynx cancer Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000011469 lymphodepleting chemotherapy Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 201000002575 ocular melanoma Diseases 0.000 description 2
- 201000006958 oropharynx cancer Diseases 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 208000010626 plasma cell neoplasm Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- 208000037965 uterine sarcoma Diseases 0.000 description 2
- 201000011531 vascular cancer Diseases 0.000 description 2
- 206010055031 vascular neoplasm Diseases 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- 101100005768 Arabidopsis thaliana CDF3 gene Proteins 0.000 description 1
- 101100187180 Arabidopsis thaliana LTP2 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000016904 Armadillo Domain Proteins Human genes 0.000 description 1
- 108010014223 Armadillo Domain Proteins Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 102100038077 CD226 antigen Human genes 0.000 description 1
- 241000282470 Canis latrans Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 241000499489 Castor canadensis Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241001481833 Coryphaena hippurus Species 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000289632 Dasypodidae Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283070 Equus zebra Species 0.000 description 1
- 241001481760 Erethizon dorsatum Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 241000282816 Giraffa camelopardalis Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000060234 Gmelina philippensis Species 0.000 description 1
- 241000282821 Hippopotamus Species 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 241001233242 Lontra Species 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 241000721701 Lynx Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000289581 Macropus sp. Species 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 241000283082 Megaptera novaeangliae Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 235000011779 Menyanthes trifoliata Nutrition 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000121185 Monodon monoceros Species 0.000 description 1
- 206010028193 Multiple endocrine neoplasia syndromes Diseases 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001504654 Mustela nivalis Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 description 1
- 241000283220 Odobenus rosmarus Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 1
- 241000283283 Orcinus orca Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241000282372 Panthera onca Species 0.000 description 1
- 241000282373 Panthera pardus Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004107 Penicillin G sodium Substances 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 241001520299 Phascolarctos cinereus Species 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
- 241000282330 Procyon lotor Species 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000008938 Rhabdoid tumor Diseases 0.000 description 1
- 206010073334 Rhabdoid tumour Diseases 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010044407 Transitional cell cancer of the renal pelvis and ureter Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241001147416 Ursus maritimus Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000018554 digestive system carcinoma Diseases 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 208000014616 embryonal neoplasm Diseases 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 208000032099 esthesioneuroblastoma Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 208000003884 gestational trophoblastic disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 201000008893 intraocular retinoblastoma Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 229960003278 osimertinib Drugs 0.000 description 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 235000019369 penicillin G sodium Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 238000005222 photoaffinity labeling Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 230000037048 polymerization activity Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 208000030859 renal pelvis/ureter urothelial carcinoma Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000037969 squamous neck cancer Diseases 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- ADCC antibody dependent cell-mediated cytotoxicity
- NK cells are immune cells that can engage tumor cells through a complex array of receptors on their cell surface, as well as through antibody-dependent cellular cytotoxicity (ADCC). To initiate ADCC, NK cells engage with antibodies via the CD16 receptor on their surface. NK cells may have an advantage over other immune cells, such as the T cells used in CAR-T cell therapy and other cell therapies. In an exemplary advantage, NK cells can be used as allogeneic therapies, meaning that NK cells from one donor can be safely used in one or many patients without the requirement for HLA matching, gene editing, or other genetic manipulations. Allogeneic NK cells with anti-tumor activity can be administered safely to patients without many of the risks associated with T cell therapies, such as severe cytokine release syndrome (CRS), and neurological toxicities or graft versus host disease (GvHD).
- CRS severe cytokine release syndrome
- GvHD graft versus host disease
- Allogeneic NK cells may provide an important treatment option for cancer patients.
- NK cells have been well tolerated without evidence of graft-versus-host disease, neurotoxicity or cytokine release syndrome associated with other cell- based therapies.
- NK cells do not require prior antigen exposure or expression of a specific antigen to identify and lyse tumor cells.
- NK cells have the inherent ability to bridge between innate immunity and engender a multi-clonal adaptive immune response resulting in long-term anticancer immune memory.
- NK cells can recruit and activate other components of the immune system.
- Activated NK cells secrete cytokines and chemokines, such as interferon gamma (IFN ⁇ ); tumor necrosis factor alpha (TNF ⁇ ); and macrophage inflammatory protein 1 (MIP1) that signal and recruit T cells to tumors.
- IFN ⁇ interferon gamma
- TNF ⁇ tumor necrosis factor alpha
- MIP1 macrophage inflammatory protein 1
- cords with preferred characteristics for enhanced clinical activity can be selected by utilizing a diverse umbilical cord blood bank as a source for NK cells.
- KIR Killer cell Immunoglobulin-like Receptor
- the administration of the allogenic NK cells, as described herein, can enhance patients’ ADCC responses, e.g., in combination with a multispecific engager, e.g., a multispecific engager described herein.
- compositions comprising: (a)a natural killer cell (NK cell) comprising a KIR-B haplotype and expression of a CD16 molecule; and (b)a bispecific antibody or antigen binding fragment thereof compri sing a first binding domain that specifically binds to CD 16 (Fc ⁇ RIII) and a second binding domain that specifically binds to CD30, wherein the first binding domain that, specifically binds to CD16 comprises: a light chain variable domain (VL_CDI6A) comprising a light chain complementarity determining region 1 (CDRL1) comprising SEQ ID NO: 9, a light chain complementarity determining region 2 (CDRL2) comprising SEQ ID NO: 10; a light chain complementarity determining region 3 (CDRL3) comprising SEQ ID NO: 11; and a heavy chain variable domain (VH_CD16A) comprising a heavy chain complementarity determining region 1 (CDRH1 comprising SEQ ID NO: 6; a heavy chain complementarity
- VL_CDI6A compris
- the CD 16 molecule comprises a V/V polymorphism at
- the bispecific antibody that specifically binds to CD 16 specifically binds to CD16A.
- the first binding domain that specifically binds to CD 16 comprises a light chain variable (VL) region comprising SEQ ID NO: 20 and a heavy chain variable (V H ) region comprising SEQ ID NO: 19.
- VL light chain variable
- V H heavy chain variable
- the first binding domain that specifically binds to CD 16 comprises a VL region comprising an amino acid sequence having or having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 20 and a V H region comprising an amino acid sequence having or having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 19.
- the second binding domain that specifically binds to CD30 comprises a light chain variable (VL) region comprising SEQ ID NO: 22 and a heavy chain variable (V H ) region comprising SEQ ID NO: 21.
- VL light chain variable
- V H heavy chain variable
- the second binding domain that specifically binds to CD30 comprises a VL region comprising an amino acid sequence having or having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 22 and a V H region comprising an amino acid sequence having or having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 21.
- the bispecific antibody or antigen binding fragment thereof is a bispecific antigen binding fragment; and the variable domains of the bispecific antigen binding fragment are linked by peptide linkers L 1, L2, and L3 from the N-terminus to the C- terminus in the order: VH_CD30 - L 1 - VL, CD16A - L2 - VH_CD16A - L3 - VL_CD30.
- each of peptide linkers L 1, L2, and L3 consist of no more than 12 amino acid residues.
- linker L,2 of the antibody construct consists of between 3 and 9 amino acid residues, inclusive.
- the bispecific antibody or antigen binding fragment thereof is a bi specific antigen binding fragment; and the variable domains of the bispecific antigen binding fragment are linked by peptide linkers L 1, L2, and L3 from the N-terminus to the C- terminus in the order: VH_CD16A - L1 - VL_CD30 - L2 - VH_CD30 - L3 - VL_CD16A.
- each of peptide linkers L 1, L2, and L3 consist of no more than 12 amino acid residues.
- linker L2 of the antibody construct consists of between 3 and 9 amino acid residues, inclusive.
- the bispecific antibody or antigen binding fragment thereof is a comprises an amino acid sequence having or having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 18.
- the bispecific antibody or antigen binding fragment thereof is a bispecific antigen binding fragment comprising an amino acid sequence set forth in SEQ ID NO: 18.
- the NK cell is a cord blood-derived NK cell.
- the cord blood-derived NK cell has been produced by a method comprising: (a) providing a sample of cord blood cells comprising natural killer cells, (b) depleting the cells of CD3(+) cells; (b) expanding the natural killer cells by culturing the seed cells with a first plurality of cells from an inactivated CD4(+) T cell line in a medium comprising: a T-cell stimulating antibody selected from the group consisting of OKT3, UCHT1, HTa, or a combination thereof; and IL-2, to produce the cord blood-derived natural killer cells.
- the inactivated CD4(+) T cell line expresses at least one gene selected from the group consi sting of a 4-1 BBL gene, a membrane-bound IL-21 (mbIL-21) gene, an OX40L gene, and a mouse TNF- ⁇ gene.
- the inactivated CD4(+) T cell line expresses a 4-1BBL gene, a membrane-bound IL-21 (mb IL-21) gene, and a mouse TNF- ⁇ gene.
- the first binding domain that specifically binds to CD 16 of the bispecific antibody or antigen binding fragment thereof is bound to the CD16 molecule of the NK cell.
- the pharmaceutical composition further comprises: (a) human albumin; (b) dextran; (c) glucose; (d) DMSO; and (e) a buffer.
- the pharmaceutical composition comprises a pharmaceutically acceptable excipient.
- frozen vials comprising any of the pharmaceutical compositions described herein.
- Also described herein are methods for treating a patient suffering from a CD30 + cancer comprising administering any of the pharmaceutical compositions described herein.
- Also described herein are methods for treating a patient suffering from a CD30 + cancer comprising: administering a first pharmaceutical composition comprising a natural killer cell (NK cell) comprising a KIR-B haplotype and expression of a CD16 molecule; and administering a second pharmaceutical composition comprising a bispecific antibody or antigen binding fragment thereof comprising a first binding domain that specifically binds to CD16 (Fc ⁇ RIII) and a second binding domain that specifically binds to CD30, wherein the first binding domain that specifically binds to CD16 comprises: a light chain variable domain (VL_CD16A) comprising a light chain complementarity determining region 1 (CDRL 1 ) comprising SEQ ID NO: 9, a light chain complementarity determining region 2 (CDRL2) comprising SEQ ID NO: 10; a light chain complementarity determining region 3 (CDRL3) comprising SEQ ID NO: 11; and a heavy chain variable domain ( VH_CD 16 A) comprising a heavy chain complementarity determining region
- the NK cell is a cord blood-derived NK cell.
- the cord blood-derived NK cell has been produced by a method comprising: (a) providing a sample of cord blood cells comprising natural killer cells; (b) depleting the cells of CD3(+) cells; (b) expanding the natural killer cells by culturing the seed cells with a first plurality of cells from an inactivated CD4(+) T cell line in a medium comprising: a T-cell stimulating antibody selected from the group consisting of OKT3, UCHTI, HTa, or a combination thereof; and IL-2, to produce the cord blood-derived natural killer cells.
- the inactivated CD4(+) T cell line expresses at least one gene selected from the group consisting of a 4-1BBL gene, a membrane-bound IL-21 (mbIL-21) gene, an OX40L gene, and a mouse TNF- ⁇ gene.
- the inactivated CD4(+) T cell line expresses a 4-1BBL gene, a membrane-bound IL -21 (mbIL-21) gene, and a mouse TNF- ⁇ gene.
- the CD16 molecule is a CD16A molecule.
- the CD 16 molecule comprises a V/V polymorphism at
- the first binding domain that specifically binds to CD16 specifically binds to CD 16 A.
- the pharmaceutical composition further comprises: (a) human albumin; (b) dextran; (c) glucose; (d) DMSO; and (e) a buffer.
- the first pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
- the first binding domain that specifically binds to CD 16 comprises a light chain variable (V L ) region comprising SEQ ID NO: 20 and a heavy chain variable (V H ) region comprising SEQ ID NO: 19.
- the first binding domain that specifically binds to CD16 comprises a VL region comprising an amino acid sequence having or having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 20 and a V H region comprising an amino acid sequence having or having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 19.
- the second binding domain that specifically binds to CD30 comprises a light chain variable (V L ) region comprising SEQ ID NO: 22 and a heavy chain variable (V H ) region comprising SEQ ID NO: 21.
- the second binding domain that specifically binds to CD30 comprises a VL region comprising an amino acid sequence having or having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 22 and a V H region comprising an amino acid sequence having or having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 21.
- the bispecific antibody or antigen binding fragment thereof is a bi specific antigen binding fragment; and the variable domains of the bispecific antigen binding fragment are linked by peptide linkers L 1 , L2, and L.3 from the N-tenninus to the C- terminus in the order: VH_CD30 -- L 1 - VL_CD16A - L2 - VH_CD16A - L3 - VL_CD30.
- the bispecific antibody or antigen binding fragment thereof is a bispecific antigen binding fragment; and the variable domains of the bispecific antigen binding fragment are linked by peptide linkers L 1, L2, and L3 from the N-terminus to the C-terminus in the order: VH_CD16A - L 1- VL_CD30 - L2 - VH_CD30 - L3 - VL_CD 16 A.
- each of peptide linkers L 1, L2, and L3 consist of no more than 12 amino acid residues.
- linker L2 of the antibody construct consists of between 3 and 9 amino acid residues, inclusive.
- the bispecific antibody or antigen binding fragment thereof is a comprises an amino acid sequence having or having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 18.
- the bispecific antibody or antigen binding fragment thereof is a bispecific antigen binding fragment comprising an amino acid sequence set forth in SEQ ID NO: 18.
- FIG. 1 shows an exemplary embodiment of a method for NK cell expansion and stimulation.
- FIG. 2 shows cytotoxic activity of AFM13 and AB-101 NK cells from MCB2, in 4 hour calcein-release assays on KARPAS-299 target cells at decreasing effector-to-target (E:T) ratios starting at 10: 1 followed by two-fold serial dilutions.
- FIG. 3 shows cytotoxic activity of AFM13 and AB- 101 NK cells from MCB 1, in 4 hour calcein-release assays on KARPAS-299 target cells at decreasing effector-to-target (E:T) ratios starting at 10: 1 followed by two-fold serial dilutions.
- FIG. 4 shows a bar graph of cytotoxic activity of AFM13 and AB-101 NK cells from MCB1 (right, AB-101 MCB1) and of MCB2 (left, AB-101 MCB2), in 4 hour calcein- release assays on KARPAS-299 target cells at an effector-to-target (E:T) ratio of 5 : 1.
- FIG. 5 show's retention of bound AFM13 on preloaded cryopreserved AB-101 cells from MCB2 after thawing, wherein filled histograms represent anti-AFM13 (rat anti- AFM13 antibody) + secondary antibody (goat anti-rat FITC antibody) and open histograms represent secondary antibody only. From top to bottom: non-preloaded; non-preloaded + fresh excess AFM; AFM-preloaded; AFM-preloaded + fresh excess AFM.
- FIG. 6 show's retention of bound AFM13 on preloaded cryopreserved AB- 101 cells from MCB1 after thawing, wherein filled histograms represent anti-AFM13 (rat anti- AFM13 antibody) + secondary antibody (goat anti-rat FITC antibody) and open histograms represent, secondary antibody only. From top to bottom: non-preloaded; non-preloaded + fresh excess AFM; AFM-preloaded; .AFM-preloaded + fresh excess AFM.
- FIG. 7 shows fluorescence intensity on CD 16 expression on preloaded AB-101 cells (left: MCB2, right: MCB1).
- the various conditions show uniform expression of CD 16 on AB-101 cells. From top to bottom: non-preloaded; non-preloaded + fresh excess AFM; AFM- preloaded; AFM-preloaded + fresh excess AFM.
- FIG. 8 shows NK fratricide (NK-NK cell lysis) by AFM13 on AB-101 NK cells from MCB2, in 4 hour calcein-release assays at an effector-to-target (E:T) ratio of 1 : 1.
- FIG. 9 shows NK fratricide (NK-NK cell lysis) by AFM13 on AB-101 NK cells from MCB1, in 4 hour calcein-release assays at an effector-to-target (E:T) ratio of 1:1.
- FIG. 10 show's up-regulation of CD 107a in response to Karpas-299 target cells and AFM13, wherein the AB-101 NK cells from MCB2 were co-cultured with and without the target cells at a 1 : 1 cell ratio, wherein the %CD107a+ NK cells was determined by flow cytometry/.
- FIG. 11 show's up-regulation of CD107a in response to Karpas-299 target cells and AFM13, wherein the AB-101 NK cells from MCB1 were co-cultured with and without the target cells at a 1 : 1 cell ratio, wherein the %CD107a+ NK cells was determined by flow cytometry.
- FIG. 12 shows increased production of intracel lular IFNy in response to Karpas- 299 target cells and AI M 13. wherein the AB-101 NK cells from MCB2 were co-cultured with and without the target cells at a 1 : 1 cell ratio, wherein the %IFN ⁇ + NK cells was determined by flow cytometry/.
- FIG. 13 shows increased production of intracellular IFNy in response to Karpas- 299 target cells and AFM13, wherein the AB-101 NK cells from MCB1 were co-cultured with and without the target cells at a 1 : 1 cell ratio, wherein the %IFN ⁇ + NK cells was determined by flow cytometry.
- FIG. 14 shows viability analysis of cryopreserved AFM 13 -preloaded AB-101 NK cells, wherein the efficacy of AFM 13 -preloaded or empty AB-101 NK cells were evaluated on MDA-MB-23 1-Luc cells in an intraperitoneal xenograft tumor model in female hILl 5-NOG mice.
- compositions comprising NK cell(s), e.g., as described herein, and multispecific engager(s), e.g., as described herein as well as frozen vial(s) comprising the pharmaceutical composition(s), and methods for treating patients with the pharmaceutical composition(s).
- natural killer cells are expanded and stimulated, e.g., by culturing and stimulation with feeder cells.
- NK cells can be expanded and stimulated as described, for example, in US 2020/0108096 or WO 2020/101361 , both of winch are incorporated herein by reference in their entirety. Briefly, the source cells can be cultured on modified HuT-78 (ATCC® TIB-161TM) cells that, have been engineered to express 4-1 BBL, membrane bound IL-21, and a mutant TNFa as described in US 2020/0108096.
- modified HuT-78 ATCC® TIB-161TM
- Suitable NK cells can also be expanded and stimulated as described herein.
- NK cells are expanded and stimulated by a method comprising: (a) providing NK cells, e.g., a composition comprising NK cells, e.g., CD3(+) depleted NK cells; and (b) culturing in a medium comprising feeder cells and/or stimulation factors, thereby producing a population of expanded and stimulated NK cells.
- NK cells e.g., a composition comprising NK cells, e.g., CD3(+) depleted NK cells
- culturing in a medium comprising feeder cells and/or stimulation factors thereby producing a population of expanded and stimulated NK cells.
- the NK cell source is selected from the group consisting of peripheral blood, peripheral blood lymphocytes (PBLs), peripheral blood mononuclear cells (PBMCs), bone marrow, umbilical cord blood, isolated NK cells, NK cells derived from induced pluripotent stem cells, NK cells derived from embryonic stem cells, and combinations thereof.
- PBLs peripheral blood lymphocytes
- PBMCs peripheral blood mononuclear cells
- umbilical cord blood isolated NK cells
- NK cells derived from induced pluripotent stem cells NK cells derived from embryonic stem cells, and combinations thereof.
- the NK cell source is a single unit of cord blood.
- the natural killer cell source e.g., single unit of cord blood
- the natural killer cell source comprises from or from about 1 x 10 7 to or to about 1 x 10 9 total nucleated cells.
- the natural killer cell source e.g., single unit of cord blood
- the natural killer cell source comprises from or from about 1 x 10 8 to or to about 1.5 x 10 8 total nucleated cells.
- the natural killer cell source e.g., single unit of cord blood
- the natural killer cell source, e.g., single unit, of cord blood comprises about 1 x 10 8 total nucleated cells.
- the natural killer cell source e.g., single unit of cord blood
- the natural killer cell source comprises 1 x 10 9 total nucleated cells.
- the natural killer cell source e.g., single unit of cord blood
- the NK cell source e.g., the cord blood unit
- the NK cell source comprises from about 20% to about 80% CD16+ cells.
- the NK cell source e.g., the cord blood unit
- the NK cell source e.g., the cord blood unit, comprises less than or equal to 80% CD16+ cells.
- the NK cell source e.g., the cord blood unit, comprises less than or equal to 40%, e.g., less than or equal to 30%, e.g., less than or equal to 20%, e.g., less than or equal to 10%, e.g., less than or equal to 5% Ml. (12 A cells.
- the NK cell source e.g., the cord blood unit
- the NK cell source comprises less than or equal to 40%, e.g., less than or equal to 30%, e.g., less than or equal to 20%, e.g., less than or equal to 10%, e.g., less than or equal to 5% NKG2C+ cells.
- the NK cell source e.g., the cord blood unit
- the NK cell source comprises less than or equal to 40%, e.g., less than or equal to 30%, e.g., less than or equal to 20%, e.g., less than or equal to 10%, e.g., less than or equal to 5% NKG2D+ cells.
- the NK cell source e.g., the cord blood unit
- the cord blood unit comprises less than or equal to 40%, e.g., less than or equal to 30%, e.g., less than or equal to 20%, e.g., less than or equal to 10%, e.g., less than or equal to 5% NKp46+ cells.
- the NK cell source e.g., the cord blood unit, comprises less than or equal to 40%, e.g., less than or equal to 30%, e.g., less than or equal to 20%, e.g., less than or equal to 10%, e.g., less than or equal to 5% NKp30+ cells.
- the NK cell source e.g., the cord blood unit
- the cord blood unit comprises less than or equal to 40%, e.g., less than or equal to 30%, e.g., less than or equal to 20%, e.g., less than or equal to 10%, e.g., less than or equal to 5% DNAM-1 + cells.
- the NK cell source e.g., the cord blood unit
- the cord blood unit comprises less than or equal to 40%, e.g., less than or equal to 30%, e.g., less than or equal to 20%, e.g., less than or equal to 10%, e.g., less than or equal to 5% NKp44+ cells.
- the NK cell source e.g., the cord blood unit
- the cord blood unit comprises less than or equal to 40%, e.g., less than or equal to 30%, e.g., less than or equal to 20%, e.g., less than or equal to 10%, e.g., less than or equal to 5% CD25+ cells.
- the NK cell source e.g., the cord blood unit, comprises less than or equal to 40%, e.g., less than or equal to 30%, e.g., less than or equal to 20%, e.g., less than or equal to 10%, e.g., less than or equal to 5% CD62L+ cells.
- the NK cell source e.g., the cord blood unit
- the cord blood unit comprises less than or equal to 40%, e.g., less than or equal to 30%, e.g., less than or equal to 20%, e.g., less than or equal to 10%, e.g., less than or equal to 5% CD69+ cells.
- the NK cell source e.g., the cord blood unit, comprises less than or equal to 40%, e.g., less than or equal to 30%, e.g., less than or equal to 20%, e.g., less than or equal to 10%, e.g., less than or equal to 5% CXCR3+ cells.
- the NK cell source e.g., the cord blood unit
- the cord blood unit comprises less than or equal to 40%, e.g., less than or equal to 30%, e.g., less than or equal to 20%, e.g., less than or equal to 10%, e.g., less than or equal to 5% CD57+ cells.
- NK cells in the NK cell source comprise a KIR B allele of the KIR receptor family.
- KIR Killer Cell Immunoglobulin-Like Receptor
- NK cells in the NK cell source comprise the 158 V/V variant of CD16. See, e.g., Koene et al., “Fc ⁇ RIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcgammaRIIIa, Independently of the FcgammaRIIIa- 48L/R/H Phenotype,” Blood 90: 1109—14 (1997).
- NK cells in the cell source comprises both the KIR B allele of the KIR receptor family and the 158 V/V variant of CD16.
- the NK cell source is CD3 ⁇ +) depleted.
- the method comprises depleting the NK cell source of CD3(+) cells.
- depleting the NK cell source of CD3(+) cells comprises contacting the NK cell source with a CD3 binding antibody or antigen binding fragment thereof.
- the CD3 binding antibody or antigen binding fragment thereof is selected from the group consisting of OKT3, UCHT1, and HIT3a, and fragments thereof.
- the CD3 binding antibody or antigen binding fragment thereof is OKT3 or an antigen binding fragment thereof.
- the antibody or antigen binding fragment thereof is attached to a bead, e.g., a magnetic bead.
- the depleting the composition of CD3(+) cells comprises contacting the composition with a CD3 targeting antibody or antigen binding fragment thereof attached to a bead and removing the bead-bound CD3(+) cells from the composition.
- the composition can be depleted of CD3 cells by immunomagnetic selection, for example, using a CliniMACS T cell depletion set ((LS Depletion set (162-01 ) Miltenyi Biotec).
- Feeder cells can be used to stimulate the NK cells and help them to expand more quickly, e.g., by providing substrate, growth factors, and/or cytokines.
- NK cells can be stimulated using various types of feeder cells, including, but not limited to peripheral blood mononuclear cells (PBMC), Epstein-Barr virus-transformed B- lymphoblastoid cells (e.g., EBV-LCL), myelogenous leukemia cells (e.g., K562), and CD4(+) T cells (e.g., HuT), and derivatives thereof.
- PBMC peripheral blood mononuclear cells
- EBV-LCL Epstein-Barr virus-transformed B- lymphoblastoid cells
- myelogenous leukemia cells e.g., K562
- CD4(+) T cells e.g., HuT
- the feeder cells are inactivated, e.g., by ⁇ -irradiation or mitomycin-c treatment.
- feeder cell(s) are inactivated CD4(+) T ceil(s).
- the inactivated CD4(+) T cell(s) are HuT-78 cells (ATCC® TIB-161TM) or variants or derivatives thereof.
- the HuT-78 derivative is H9 (ATCC® HTB-176TM).
- the inactivated CD4(+) T cell(s) express OX40L.
- the inactivated CD4(+) T cell(s) are HuT-78 cells or variants or derivatives thereof that express OX40L (SEQ ID NO: 4) or a variant thereof.
- the feeder cells are HuT-78 cells engineered to express at least one gene selected from the group consisting of 4-1BBL (UniProtKB P41273, SEQ ID NO: 1), membrane bound IL-21 (SEQ ID NO: 2), and membrane bound TNFalpha (SEQ ID NO: 3) (“eHut-78 cells”), or variants thereof.
- the inactivated CD4(+) T cell(s) are HuT-78 (ATCC® TIB-161TM) cell s or variants or derivatives thereof that express an ortholog of OX40L, or variant thereof.
- the feeder cells are HuT-78 cells engineered to express at least one gene selected from the group consisting of an 4-1BBL ortholog or variant thereof, a membrane bound IL-21 ortholog or variant thereof, and membrane bound TNFalpha ortholog, or variant thereof.
- the feeder cells are HuT-78 cell(s) that express OX40L (SEQ ID NO: 4) and are engineered to express 4-1BBL (SEQ ID NO: 1), membrane bound IL- 21 (SEQ ID NO: 2), and membrane bound TNFalpha (SEQ ID NO: 3) (“eHut-78 cells”) or variants or derivatives thereof.
- the feeder cells are expanded, e.g., from a frozen stock, before culturing with NK cells, e.g., as described in Example 2.
- NK cells can also be stimulated using one or more stimulation factors other than feeder cells, e.g., signaling factors, in addition to or in place of feeder cells.
- stimulation factors other than feeder cells, e.g., signaling factors, in addition to or in place of feeder cells.
- the stimulating factor e.g., signaling factor
- the stimulating factor is a component of the culture medium, as described herein.
- the stimulating factor e.g., signaling factor
- the stimulation factor(s) are cytokine(s).
- the cytokine(s) are selected from the group consisting of IL-2, IL-12, IL-15, IL- 18, IL-21, IL-23, IL-27, IFN- ⁇ , IFN ⁇ , and combinations thereof.
- the cytokine is IL-2.
- the cytokines are a combination of IL-2 and IL-15.
- the cytokines are a combination of IL-2, IL-15, and IL-18.
- the cytokines are a combination of IL-2, IL-18, and IL-21 .
- the NK cells can be expanded and stimulated by co-culturing an ⁇ K cell source and feeder cells and/or other stimulation factors. Suitable NK. cell sources, feeder cells, and stimulation factors are described herein.
- the culture medium is a basal culture medium, optionally supplemented with additional components, e.g., as described herein.
- the culture medium e.g., the basal culture medium
- the culture medium is a serum-free culture medium.
- the culture medium e.g., the basal culture medium, is a serum-free culture medium supplemented with human plasma and/or serum.
- Suitable basal culture media include, but are not limited to, DMEM, RPMI 1640, MEM, DMEM/F12, SCGM (CellGenix®, 20802-0500 or 20806-0500), LGM-3TM (Lonza, CC- 3211), TexMACSTM(Miltenyi Biotec, 130-097-196), ALySTM 505NK-AC (Cell Science and Technology Institute, Inc., 01600P02), ALySTM 505NK-EX (Cell Science and Technology Institute, Inc., 01400P10), CTSTM AIM-VTM SFM (ThermoFisher Scientific, A3830801), CTSTM OpTmizerTM (ThermoFisher Scientific, A1048501, ABS-00I, StemXxVivoand combinations thereof.
- the culture medium may comprise additional components, or be supplemented with additional components, such as growth factors, signaling factors, nutrients, antigen binders, and the like. Supplementation of the culture medium may occur by adding each of the additional component or components to the culture vessel either before, concurrently with, or after the medium is added to the culture vessel.
- the additional component or components may be added together or separately. When added separately, the additional components need not be added at the same time.
- the culture medium comprises plasma, e.g., human plasma.
- the culture medium is supplemented with plasma, e.g., human plasma.
- the plasma e.g., human plasma, comprises an anticoagulant, e.g., trisodium citrate.
- the medium comprises and/or is supplemented with from or from about 0.5 % to or to about 10 % v/v plasma, e.g., human plasma.
- the medium is supplemented with from or from about 0.5% to or to about 9%, from or from about 0.5% to or to about 8%, from or from about 0.5% to or to about 7%, from or from about 0.5% to or to about 6%, from or from about 0.5% to or to about 5%, from or from about 0.5% to or to about 4%, from or from about 0.5% to or to about 3%, from or from about 0.5% to or to about.
- the culture medium comprises and/or is supplemented with from 0.8% to1.2% v/v human plasma. In some embodiments, the culture medium comprises and/or is supplemented with 1.0 % v/v human plasma. In some embodiments, the culture medium comprises and/or is supplemented with about 1.0 % v/v human plasma.
- the culture medium comprises serum, e.g., human serum. In some embodiments, the culture medium is supplemented with serum, e.g., human serum. In some embodiments, the serum is inactivated, e.g., heat inactivated. In some embodiments, the serum is filtered, e.g., sterile-filtered.
- the culture medium comprises glutamine. In some embodiments, the culture medium is supplemented with glutamine. In some embodiments, the culture medium comprises and/or is supplemented with from or from about 2.0 to or to about 6.0 mM glutamine.
- the culture medium comprises and/or is supplemented with from or from about 2.0 to or to about 5,5, from or from about 2.0 to or to about 5.0, from or from about 2.0 to or to about 4.5, from or from about 2.0 to or to about 4.0, from or from about 2.0 to or to about 3.5, from or from about 2.0 to or to about 3.0, from or from about 2.0 to or to about 2.5, from or from about 2.5 to or to about 6.0, from or from about 2.5 to or to about 5.5, from or from about 2.5 to or to about 5.0, from or from about 2.5 to or to about 4.5, from or from about 2.5 to or to about 4.0, from or from about 2.5 to or to about 3.5, from or from about 2.5 to or to about 3.0, from or from about 3.0 to or to about 6.0, from or from about 3.0 to or to about 5.5, from or from about 3.0 to or to about 5.0, from or from about 3.0 to or to about 4.5, from or from about 3.0 to or to about 4.0, from or from about 3.0 to
- the culture medium comprises and/or is supplemented with from 3.2 mM glutamine to 4.8 mM glutamine. In some embodiments, the culture medium comprises and/or is supplemented with 4.0 mM glutamine. In some embodiments, the culture medium comprises and/or is supplemented with about 4.0 mM glutamine.
- the culture medium comprises one or more cyotkines. In some embodiments, the culture medium is supplemented with one or more cyotkines.
- the cytokine is selected from IL-2, IL-12, IL-15, IL- 18, and combinations thereof.
- the culture medium comprises and/or is supplemented with IL-2. In some embodiments, the culture medium comprises and/or is supplemented with from or from about 150 to or to about 2,500 IU/mL IL-2. In some embodiments, the culture medium comprises and/or is supplemented with from or from about 200 to or to about 2,250, from or from about 200 to or to about 2,000, from or from about 200 to or to about 1,750, from or from about 200 to or to about 1,500, from or from about 200 to or to about 1,250, from or from 200 to or to about 1,000, from or from about 200 to or to about 750, from or from about 200 to or to about 500, from or from about 200 to or to about 250, from or from about 250 to or to about 2,500, from or from about 250 to or to about 2,250, from or from about 250 to or to about 2,000, from or from about 250 to or to about 1,750, from or from about 250 to or to about 1,500, from or from about 250 to or to about 1,250,
- the culture medium comprises and/or is supplemented with from 64 ⁇ g/L to 96 ⁇ g/L IL-2. In some embodiments, the culture medium comprises and/or is supplemented with 80 ⁇ g/L IL-2 (approximately 1,333 lU/mL). In some embodiments, the culture medium comprises and/or is supplemented with about 80 ⁇ g/L.
- the culture medium comprises and/or is supplemented with a combination of IL-2 and IL-15.
- the culture medium comprises and/or is supplemented with a combination of IL-2, IL-15, and IL-18.
- the culture medium comprises and/or is supplemented with a combination of IL-2, IL-18, and IL-21 , [0123] In some embodiments, the culture medium comprises and/or is supplemented with glucose. In some embodiments, the culture medium comprises and/or is supplemented with from or from about 0.5 to or to about 3.5 g/'L glucose.
- the culture medium comprises and/or is supplemented with from or from about 0.5 to or to about 3.0, from or from about 0.5 to or to about 2.5, from or from about 0.5 to or to about 2.0, from or from about 0.5 to or to about 1.5, from or from about 0.5 to or to about 1.0, from or from about 1.0 to or to about 3.0, from or from about 1.0 to or to about 2.5, from or from about 1.0 to or to about 2.0, from or from about 1.0 to or to about 1.5, from or from about 1.5 to or to about 3.0, from or from about 1.5 to or to about 2.5, from or from about 1.5 to or to about 2.0, from or from about 2.0 to or to about 3.0, from or from about 2.0 to or to about 2.5, or from or from about 2.5 to or to about 3.0 g/L glucose.
- the culture medium comprises and/or is supplemented with from 1 .6 to 2.4 g/L glucose. In some embodiments, the culture medium comprises and/or is supplemented with 2.0 g/L glucose. In some embodiments, the culture medium comprises about 2.0 g/L glucose.
- the culture medium comprises and/or is supplemented with sodium pyruvate. In some embodiments, the culture medium comprises and/or is supplemented with from or from about 0. 1 to or to about 2.0 mM sodium pyruvate. In some embodiments, the culture medium comprises and/or i s supplemented with from or from about.
- 0.1 to or to about 1.8 from or from about 0.1 to or to about 1.6, from or from about 0.1 to or to about 1.4, from or from about 0.1 to or to about 1.2, from or from about 0.1 to or to about 1.0, from or from about 0.1 to or to about 0.8, from or from about 0.1 to or to about 0.6, from or from about 0.1 to or to about 0.4, from or from about 0.
- 0.4 to or to about 1.8 from or from about 0.4 to or to about 1.6, from or from about 0.4 to or to about 1.4, from or from about 0.4 to or to about 1.2, from or from about 0.4 to or to about 1.0, from or from about 0.4 to or to about 0.8, from or from about 0.4 to or to about 0.6, from or from about 0.6 to or to about 2.0, from or from about 0.6 to or to about 1 .8, from or from about 0.6 to or to about 1.6, from or from about 0.6 to or to about 1.4, from or from about 0.6 to or to about 1.2, from or from about 0.6 to or to about 1.0, from or form about 0.6 to or to about 0.8, from or from about 0.8 to or to about 2.0, from or from about 0.8 to or to about 1.8, from or from about 0.8 to or to about 1 .6, from or from about 0.8 to or to about 1 .4, from or from about 0.8 to or to about 1.4, from or from about 0.8 to or to about
- the culture medium comprises from 0.8 to 1.2 mM sodium pyruvate. In some embodiments, the culture medium comprises 1.0 mM sodium pyruvate. In some embodiments, the culture medium comprises about 1.0 mM sodium pyuruvate.
- the culture medium comprises and/or is supplemented with sodium hydrogen carbonate. In some embodiments, the culture medium comprises and/or is supplemented with from or from about 0.5 to or to about 3.5 g/L sodium hydrogen carbonate. In some embodiments, the culture medium comprises and/or is supplemented with from or from about 0.5 to or to about 3.0, from or from about 0.5 to or to about 2.5, from or from about 0.5 to or to about 2.0, from or from about 0.5 to or to about 1.5, from or from about 0.5 to or to about 1.0, from or from about.
- the culture medium comprises and/or is supplemented with from 1.6 to 2.4 g/L sodium hydrogen carbonate. In some embodiments, the culture medium comprises and/or is supplemented with 2,0 g/L sodium hydrogen carbonate. In some embodiments, the culture medium comprises about 2.0 g/L sodium hydrogen carbonate.
- the culture medium comprises and/or is supplemented with albumin, e.g., human albumin, e.g., a human albumin solution described herein. In some embodiments, the culture medium comprises and/or is supplemented with from or from about 0.5% to or to about 3.5% v/v of a 20% albumin solution, e.g., a 20% human albumin solution. In some embodiments, the culture medium comprises and/or is supplemented with from or from about 0.5% to or to about 3.0%, from or from about 0.5% to or to about. 2.5%, from or from about 0.5% to or to about 2.0%, from or from about 0.5% to or to about 1.5%, from or from about 0.5% to or to about.
- albumin e.g., human albumin, e.g., a human albumin solution described herein.
- the culture medium comprises and/or is supplemented with from or from about 0.5% to or to about 3.5%, from or from about 0.5% to or to about. 2.5%, from or from about 0.5%
- the culture medium comprises and/or is supplemented with from 1.6% to 2.4% v/v of a 20% albumin solution, e.g., a 20% human albumin solution. In some embodiments, the culture medium comprises and/or is supplemented with 2.0% v/v of a 20% albumin solution, e.g., a 20% human albumin solution. In some embodiments, the culture medium comprises about 2.0% v/v of a 20% albumin solution, e.g., a 20% human albumin solution.
- the culture medium comprises and/or is supplemented with from or from about 2 to or to about 6 g/L albumin, e.g., human albumin. In some embodiments, the culture medium comprises and/or is supplemented with from or from about 2 to or to about 5.5, from or from about 2 to or to about 5.0, from or from about 2 to or to about 4.5, from or from about 2 to or to about 4, from or from about 2 to or to about 3.5, from or from about.
- the culture medium comprises and/or is supplemented with from 3.2 to 4.8 g/L albumin, e.g., human albumin.
- the culture medium comprises 4 g/L albumin, e.g., human albumin. In some embodiments, the culture medium comprises about 4 g/L albumin, e.g., human albumin [0128] In some embodiments, the culture medium is supplemented with Poloxamer 188. In some embodiments, the culture medium comprises and/or is supplemented with from or from about 0.1 to or to about 2.0 g/L Poloxamer 188. In some embodiments, the culture medium comprises and/or is supplemented with from or from about 0.1 to or to about 1.8, from or from about 0. 1 to or to about 1.6, from or from about 0. 1 to or to about 1.4, from or from about 0.
- 0.4 to or to about 1.2 from or from about. 0.4 to or to about 1.0, from or from about 0.4 to or to about 0.8, from or from about 0.4 to or to about 0.6, from or from about 0.6 to or to about 2.0, from or from about. 0.6 to or to about 1.8, from or from about 0.6 to or to about 1.6, from or from about 0.6 to or to about 1.4, from or from about 0.6 to or to about 1.2, from or from about 0.6 to or to about 1.0, from or form about.
- the culture medium comprises from 0.8 to 1.2 g/L Poloxamer 188. In some embodiments, the culture medium comprises 1 .0 g/L Poloxamer 188. In some embodiments, the culture medium comprises about 1.0 g/L Poloxamer 188.
- the culture medium comprises and/or is supplemented with one or more antibiotics.
- a first exemplary culture medium is set forth in Table 1 .
- a second exemplary culture medium is set forth in Table 2.
- the culture medium comprises and/or is supplemented with a CD3 binding antibody or antigen binding fragment thereof.
- the CD3 binding antibody or antigen binding fragment thereof is selected from the group consisting of OKT3, UCHT1, and HIT3a, or variants thereof.
- the CD3 binding antibody or antigen binding fragment thereof is OKT3 or an antigen binding fragment thereof.
- the CD3 binding antibody or antigen binding fragment thereof and feeder cells are added to the culture vessel before addition of NK cells and/or culture medium.
- the culture medium comprises and/or is supplemented with from or from about 5 ng/mL to or to about. 15 ng/mL OKT3.
- the culture medium comprises and/or is supplemented with from or from about 5 to or to about 12.5, from or from about 5 to or to about 10, from or from about 5 to or to about 7.5, from or from about 7.5 to or to about 15, from or from about 7.5 to or to about 12.5, from or from about 7.5 to or to about 10, from or from about 10 to or to about 15, from or from about 10 to or to about 12,5, or from or from about 12.5 to or to about 15 ng/mL OKT3.
- the culture medium comprises and/or is supplemented with 10 ng/mL OKT3.
- the culture medium comprises and/or is supplemented with about 10 ng/mL OKT3.
- the culture vessel is selected from the group consisting of a flask, a bottle, a dish, a multiwall plate, a roller bottle, a bag, and a bioreactor.
- the culture vessel is treated to render it hydrophilic. In some embodiments, the culture vessel is treated to promote attachment and/or proliferation. In some embodiments, the culture vessel surface is coated with serum, collagen, laminin, gelatin, poy-L -lysine, fibronectin, extracellular matrix proteins, and combinations thereof.
- different types of culture vessels are used for different stages of culturing.
- the culture vessel has a volume of from or from about 100 mL to or to about 1,000 L. In some embodiments, the culture vessel has a volume of or about 125 mL, of or about 250 mL, of or about 500 mL, of or about 1 L, of or about 5 L, of about 10 L, or of or about 20 L.
- the culture vessel is a bioreactor.
- the bioreactor is a rocking bed (wave motion) bioreactor. In some embodiments, the bioreactor is a stirred tank bioreactor. In some embodiments, the bioreactor is a rotating wall vessel. In some embodiments, the bioreactor is a perfusion bioreactor. In some embodiments, the bioreactor is an isolation/expansion automated system. In some embodiments, the bioreactor is an automated or semi -automated bioreactor. In some embodiments, the bioreactor is a disposable bag bioreactor.
- the bioreactor has a volume of from about 100 mL to about 1,000 L. In some embodiments, the bioreactor has a volume of from about 10 L to about 1,000 L. In some embodiments, the bioreactor has a volume of from about 100 L to about 900 L. In some embodiments, the bioreactor has a volume of from about 10 L to about 800 L. In some embodiments, the bioreactor has a volume of from about 10 L to about 700 L, about 10 L to about. 600 L, about 10 L to about 500 L, about 10 L to about 400 L, about 10 L to about.
- 300 L about 10 L to about 200 L, about 10 L to about 100 L, about 10 L to about 90 L, about 10 L to about 80 L, about 10 L to about 70 L, about 10 L to about 60 L, about 10 L to about 50 L, about 10 L to about 40 L, about 10 L to about 30 L, about 10 L to about 20 L, about 20 L to about 1,000 L, about 20 L to about 900 L, about 20 L to about 800 L, about 20 L to about 700 L, about 20 L to about 600 L, about. 20 L to about.
- 30 L to about 200 L about 30 L to about 100 L, about 30 L to about 90 L, about 30 L to about 80 L, about 30 L to about 70 L, about 30 L to about 60 L, about 30 L to about 50 L, about 30 L to about 40 L, about 40 L to about 1 ,000 L, about 40 L to about 900 L, about 40 L to about 800 L, about 40 L to about 700 L, about 40 L to about 600 L, about 40 L to about 500 L, about 40 L to about.
- 400 L about 40 L to about 300 L, about 40 L to about 200 L, about 40 L to about 100 L, about 40 L to about 90 L, about 40 L to about 80 L, about 40 L to about 70 L, about 40 L to about 60 L, about 40 L to about 50 L, about 50 L to about 1 ,000 L, about 50 L to about 900 L, about 50 L to about 800 L, about 50 L to about 700 L, about 50 L to about 600 L, about 50 L to about 500 L, about 50 L to about 400 L, about 50 L to about 300 L, about 50 L to about.
- 200 L about 50 L to about 100 L, about 50 L to about 90 L, about 50 L to about 80 L, about 50 L to about 70 L, about 50 L to about 60 L, about 60 L to about 1 ,000 L, about 60 L to about 900 L, about 60 L to about 800 L, about 60 L to about 700 L, about 60 L to about 600 L, about 60 L to about 500 L, about 60 L to about 400 L, about 60 L to about 300 L, about 60 L to about. 200 L, about 60 L to about 100L, about 60 L to about 90 L, about 60 L to about 80 L, about 60 L to about 70 L, about 70 L to about 1,000 L, about 70 L to about 900 L, about 70 L to about 800 L, about 70 L to about 700 L, about 70 L to about.
- 600 L about 70 L to about 500 L, about 70 L to about 400 L, about 70 L to about 300 L, about 70 L to about 200 L, about 70 L to about 100 L, about. 70 L to about 90 L, about 70 L to about 80 L, about 80 L to about 1,000 L, about 80 L to about 900 L, about 80 L to about 800 L, about 80 L to about 700 L, about 80 L to about 600 L, about 80 L to about 500 L, about 80 L to about 400 L, about 80 L to about 300 L, about 80 L to about 200 L, about 80 L to about 100 L, about 80 L to about 90 L, about 90 L to about 1,000 L, about 90 L to about. 900 L, about 90 L to about 800 L, about 90 L to about 700 L, about.
- the bioreactor has a volume of about 50 L.
- the bioreactor has a volume of from 100 mL to 1,000 L. In some embodiments, the bioreactor has a volume of from 10 L to 1,000 L. In some embodiments, the bioreactor has a volume of from 100 L to 900 L. In some embodiments, the bioreactor has a volume of from 10 L to 800 L.
- the bioreactor has a volume of from 10 L to 700 L, 10 L to 600 L, 10 L to 500 L, 10 L to 400 L, 10 L to 300 L, 10 L to 200 L, 10 L to 100 L, 10 L to 90 L, 10 L to 80 L, 10 L to 70 L, 10 L to 60 L, 10 L to 50 L, 10 L to 40 L, 10 L to 30 L, 10 L to 20 L, 20 L to 1,000 L, 20 L to 900 L, 20 L to 800 L, 20 L to 700 L, 20 L to 600 L, 20 L to 500 L, 20 L to 400 L, 20 L to 300 L, 20 L to 200 L, 20 L to 100 L, 20 L to 90 L, 20 L to 80 L, 20 L to 70 L, 20 L to 60 L, 20 L to 50 L, 20 L to 40 L, 20 L to 30 L, 30 L to 1,000 L, 30 L to 900 L, 30 L to 800 L, 30 L to 700 L, 30 L to 600 L, 30 L to 500 L, 30 L to 400 L, 30 L to 300
- the natural killer cell source e.g., single unit of cord blood
- the natural killer cell source is co-cultured with feeder cells to produce expanded and stimulated NK cells.
- the co-culture is carried out in a culture medium described herein, e.g., exemplary culture medium #1 (Table 1 ) or exemplary culture medium #2 (Table 2).
- the natural killer cell source e.g., single unit of cord blood
- the natural killer cell source comprises from or from about 1 x 10 7 to or to about 1 x 10 9 total nucleated cells prior to expansion.
- the natural killer cell source e.g., single unit of cord blood
- the natural killer cell source comprises from or from about 1 x 10 8 to or to about 1 .5 x 10 8 total nucleated cells prior to expansion.
- the natural killer cell source, e.g., single unit of cord blood comprises 1 x 10 8 total nucleated cells prior to expansion.
- the natural killer cell source, e.g., single unit of cord blood comprises about 1 x 10 8 total nucleated cells prior to expansion.
- the natural killer cell source e.g., single unit of cord blood
- the natural killer cell source comprises 1 x 10 9 total nucleated cells prior to expansion.
- the natural killer cell source e.g., single unit of cord blood
- cells from the co-culture of the natural killer cell source e.g., single unit of cord blood and feeder cells are harvested and frozen, e.g., in a cryopreservation composition described herein.
- the frozen cells from the co-culture are an infusion-ready drug product.
- the frozen cells from the co-culture are used as a master cell bank (MCB) from which to produce an infusion-ready drug product, e.g., through one or more additional co-culturing steps, as described herein.
- MBC master cell bank
- a natural killer cell source can be expanded and stimulated as described herein to produce expanded and stimulated NK cells suitable for use in an infusion-ready drug product without generating any intermediate products.
- a natural killer cell source can also be expanded and stimulated as described herein to produce an intermediate product, e.g., a first master cell bank (MCB).
- the first MCB can be used to produce expanded and stimulated NK cells suitable for use in an infusion-ready drug product, or, alternatively, be used to produce another intermediate product, e.g., a second MCB.
- the second MCB can be used to produce expanded and stimulated NK cells suitable for an infusion-ready drug product, or alternatively, be used to produce another intermediate product, e.g., a third MCB, and so on.
- the ratio of feeder cells to cells of the natural killer cell source or MCB cells inoculated into the co-culture is from or from about 1 : 1 to or to about 4:1.
- the ratio of feeder cells to cells of the natural killer cell source or MCB inoculated into the co-culture is 2.5: 1. In some embodiments, the ratio of feeder cells to cells of the natural killer cell source or MCB inoculated into the co- culture is about 2.5: 1.
- the co-culture is carried out in a disposable culture bag, e.g., a IL disposable culture bag.
- the co-culture is carried out in a bioreactor, e.g., a 501. bioreactor.
- culture medium is added to the co- culture after the initial inoculation.
- the co-culture is carried out for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
- the co- culture is carried out for a maximum of 16 days.
- the co-culture is carried out at 37 °C or about 37°C.
- the co-culture is carried out at pH 7.9 or about pH 7.9.
- the co-culture is carried out at a dissolved oxygen (DO) level of 50% or more.
- exemplary culture medium #1 (Table 1) is used to produce a MCB and exemplary culture medium #2 (Table 2) is used to produce cells suitable for an infusion-ready drug product.
- the co-culture of the natural killer cell source e.g., single unit of cord blood, with feeder cells yields from or from about 50 x 10 8 to or to about 50 x 10 12 cells, e.g., MCB cells or infusion-ready daig product cells.
- the expansion yields from or from about.
- 50 x 10 8 to or to about 25 x 10 10 from or from about 10 x 10 8 to or to about 1 x 10 10 , from or from about 50 x 10 8 to or to about 75 x 10 9 , from or from about 50 x 10 8 to or to about 50 x 10 9 , from or from about 50 x 10 8 to or to about 25 x 10 9 , from or from about 50 x 10 8 to or to about 1 x 10 9 , from or from about 50 x 10 8 to or to about 75 x 10 8 , from or from about 75 x 10 8 to or to about 50 x 10 10 , from or from about 75 x 10 8 to or to about 25 x 10 10 , from or from about 75 x 10 8 to or to about 1 x 10 10 , from or from about 75 x 10 8 to or to about 75 x 10 9 , from or from about 75 x 10 8 to or to about 50 x 10 9 , from or from about 75 x 10 8 to or to about 25 x 10 9 ,
- 1 x 10 9 from or from about 1 x 10 9 to or to about 50 x 10 10 , from or from about 1 x 10 9 to or to about 25 x 10 10 , from or from about 1 x 10 9 to or to about.
- 1 x 10 10 from or from about 1 x 10 9 to or to about 75 x 10 9 , from or from about 1 x 10 9 to or to about 50 x 10 9 , from or from about 1 x 10 9 to or to about 25 x 10 9 , from or from about 25 x 10 9 to or to about 50 x 10 10 , from or from about 25 x 10 9 to or to about 25 x 10 10 , from or from about 25 x 10 9 to or to about 1 x 10 10 , from or from about 25 x 10 9 to or to about 75 x 10 9 , from or from about 25 x 10 9 to or to about 50 x 10 9 , from or from about 50 x 10 9 to or to about 50 x 10 10 , from or from about 50 x
- the expansion yields from or from about 60 to or to about 100 vials, each comprising from or from about 600 million to or to about 1 billion cells, e.g., MCB cells or infusion-ready drug product cells.
- the expansion yields 80 or about 80 vials, each comprising or consisting of 800 million or about 800 million cells, e.g., MCB cells or infusion-ready drug product cells.
- the expansion yields from or from about a 100 to or to about a 500 fold increase in the number of cells, e.g., the number of MCB cells relative to the number of cells, e.g., NK cells, in the natural killer cell source.
- the expansion yields from or from about a 100 to or to about a 500, from or from about a 100 to or to about a 400, from or from about a 100 to or to about a 300, from or from about a 100 to or to about a 200, from or from about a 200 to or to about a 450, from or from about a 200 to or to about a 400, from or from about a 100 to or to about a 350, from or from about a 200 to or to about a 300, from or from about a 200 to or to about a 250, from or from about a 250 to or to about a 500, from or from about a 250 to or to about a 450, from or from about a 200 to or to about a 400, from or from about a 250 to or to about a 350, from or from about a 250 to or to about a 300, from or from about a 300 to or to about a 500, from or from about a 300 to or to about a 450, from or from or from about
- the co-culture of the MCB cells and feeder cells yields from or from about 500 million to or to about 1.5 billion cells, e.g., NK cells suitable for use in an MCB and/or in an infusion-ready drug product.
- the co-culture of the MCB cells and feeder cells yields from or from about 500 million to or to about 1.5 billion, from or from about 500 million to or to about 1.25 billion, from or from about 500 million to or to about 1 billion, from or from about 500 million to or to about 750 million, from or from about 750 million to or to about 1.5 billion, from or from about 500 million to or to about 1.25 billion, from or from about 750 million to or to about 1 billion, from or from about 1 billion to or to about 1.5 billion, from or from about 1 billion to or to about 1.25 billion, or from or from about 1.25 billion to or to about 1.5 billion cells, e.g., NK cells suitable for use in an MCB and/or an infusion-ready drug product.
- NK cells suitable for use in an MCB and/or an infusion-ready drug product.
- the co-culture of the MCB cells and feeder cells yields from or from about 50 to or to about 150 vials of cells, e.g., infusion-ready drug product cells, each comprising from or from about 750 million to or to about 1.25 billion cells, e.g., NK cells suitable for use in an MCB and/or an infusion-ready drug product.
- the co-culture of the MCB cells and feeder cells yields 100 or about 100 vials, each comprising or consisting of 1 billion or about 1 billion cells, e.g., NK cells suitable for use in an MCB and/or an infusion-ready drug product.
- the expansion yields from or from about a 100 to or to about a 500 fold increase in the number of cells, e.g., the number of NK cells suitable for use in an MCB and/or an infusion-ready drug product relative to the number of starting MCB cells.
- the expansion yields from or from about a 100 to or to about a 500, from or from about a 100 to or to about a 400, from or from about a 100 to or to about a 300, from or from about a 100 to or to about a 200, from or from about a 200 to or to about a 450, from or from about a 200 to or to about a 400, from or from about a 100 to or to about a 350, from or from about a 200 to or to about, a 300, from or from about a 200 to or to about a 250, from or from about a 250 to or to about a 500, from or from about a 250 to or to about a 450, from or from about a 200 to or to about a 400, from or from about a 250 to or to about a 350, from or from about a 250 to or to about a 300, from or from about a 300 to or to about a 500, from or from about a 300 to or to about a 450, from or from or from about
- the methods described herein can further comprise sorting engineered cells, e.g., engineered cells described herein, away from non-engineered cells.
- the engineered cells e.g., transduced cells
- the antigen of the engineered cells is a component of a CAR, e.g., a CAR described herein.
- the engineered cells e.g., transduced cells
- the non-engineered cells e.g., the non-transduced cells using flow cytometry.
- the sorted engineered cells are used as an MCB. In some embodiments, the sorted engineered cells are used as a component in an infusion -ready drug product.
- the engineered cells e.g., transduced cells
- Microfluidic cell sorting methods are described, for example, in Dalili et. al., “A Review of Sorting, Separation and Isolation of Cells and Microbeads for Biomedical Applications: Microfluidic Approaches,” Analyst 144:87 (2019).
- from or from about 1% to or to about 99% of the expanded and stimulated cells are engineered successfully, e.g., transduced successfully, e.g., transduced successfully with a vector comprising a heterologous protein, e.g., a heterologous protein comprising a CAR and/or IL- 15 as described herein. In some embodiments, from or from about 1 % to or to about 90%, from or from about.
- 1% to or to about 80% from or from about 1% to or to about 70%, from or from about 1% to or to about 60%, from or from about 1% to or to about 50%, from or from about 1% to or to about 40%, from or from about 1% to or to about 30%, from or from about 1% to or to about 20%, from or from about 1% to or to about 10%, from or from about 1% to or to about 5%, from or from about 5% to or to about 99%, from or from about 5% to or to about 90%, from or from about 5% to or to about 80%, from or from about 5% to or to about 70%, from or from about 5% to or to about 60%, from or from about 5% to or to about 50%, from or from about 5% to or to about 40%, from or from about 5% to or to about 30%, from or from about 5% to or to about 20%, from or from about 5% to or to about 10%, from or from about 10% to or to about 99%, from or from about 10% to or to about 90%, from or from about
- the expanded and stimulated cells are engineered successfully, e.g., transduced successfully, e.g., transduced successfully with a vector comprising a heterologous protein, e.g., a heterologous protein comprising a CAR and/or IL-15 as described herein.
- frozen cells of a first, or second MCB are thawed and cultured.
- a single vial of frozen cells of the first or second MCB e.g., a single vial comprising 800 or about 800 million cells, e.g., first or second MCB cells, are thawed and cultured.
- the frozen first or second MCB cells are cultured with additional feeder cells to produce cells suitable for use either as a second or third MCB or in an infusion-ready drug product.
- the cells from the co-culture of the first or second MCB are harvested and frozen.
- the cells from the co-culture of the natural killer cell source, a first MCB, or a second MCB are harvested, and frozen in a cryopreservation composition, e.g., a cryopreservation composition described herein.
- the cells are washed after harvesting.
- a pharmaceutical composition comprising activated and stimulated NK cells, e.g., activated and stimulated NK cells produced by the methods described herein, e.g., harvested and washed activated and stimulated NK cells produced by the methods described herein and a cry opreservation composition, e.g., a cry opreservation composition described herein.
- the cells are mixed with a cryopreservation composition, e.g., as described herein, before freezing.
- the cells are frozen in cryobags.
- the cells are frozen in cryovials.
- the method further comprises isolating NK cells from the population of expanded and stimulated NK cells.
- FIG. 1 An exemplary process for expanding and stimulating NK cells is shown in FIG. 1 .
- the expanded and stimulated NK cells comprises at least 80%, e.g., at least 90%, at least 95%, at least 99%, or 100% CD56+CD3- cells.
- the expanded and stimulated NK cells comprises at least 60%, e.g., at least 70%, at least 80%, at least 90% at least 95%, at least 99%, or 100% NKG2D+ cell s.
- the expanded and stimulated NK cells comprises at least 60%, e.g., at least 70%, at least 80%, at least 90% at least 95%, at least 99%, or 100% NKp46+ cells.
- the expanded and stimulated NK cells comprises at least 60%, e.g., at least 70%, at least 80%, at least 90% at least 95%, at least 99%, or 100% NKp30+ cells.
- the expanded and stimulated NK cells comprises at least 60%, e.g., at least 70%, at least 80%, at least 90% at least 95%, at least 99%, or 100% DNAM- 1+ cells.
- the expanded and stimulated NK cells comprises at least 60%, e.g., at least 70%, at least 80%, at least 90% at least 95%, at least 99%, or 100% NKp44+ cells.
- the expanded and stimulated NK cells comprises less than or equal to 20%, e.g., less than or equal to 10%, less than or equal to 5%, less than or equal to 1% or 0% CD3+ cells.
- the expanded and stimulated NK cells comprises less than or equal to 20%, e.g., less than or equal to 10%, less than or equal to 5%, less than or equal to 1% or 0% CD 14+ cells.
- the expanded and stimulated NK cells comprises less than or equal to 20%, e.g., less than or equal to 10%, less than or equal to 5%, less than or equal to 1% or 0% CD 19+ cells.
- feeder cells do not persist in the expanded and stimulated NK cells.
- multispecific engager refers to an antibody construct which is “at least bispecific”, i.e., it comprises at least a first binding domain and a second binding domain, wherein the first binding domain binds to one antigen or target (here: NK cell receptor, e.g. CD 16a), and the second binding domain binds to another antigen or target (here: the target cell surface antigen CD30).
- NK cell receptor e.g. CD 16a
- CD30 another antigen or target
- antibody constructs as defined in the context of the present disclosure comprise specificities for at least two different antigens or targets.
- the first domain preferably binds to an extracellular epitope of an NK cell receptor of one or more of the species selected from human, Macaca species and rodent species.
- Multispecific antibody constructs include, for exampie, bispecific and trispecific antibody constructs, or constructs having more than three (e.g. four, five...) specificities. Examples of multispecific antibody constructs are provided, for example, in WO 2006/125668, WO 2015/158636, WO 2017/064221, WO 2019/175368, WO 2019/198051, WO 2020/043670, WO 2021/130383, and Ellwanger et a. (MAbs. 2019 Jul, 11 (5): 899-918).
- the multispecific engager is a bispecific antibody or antigen binding fragment thereof compri sing a first binding domain that specifically binds to CDI6 (Fc ⁇ RIII) and a second binding domain that specifically binds to CD30.
- the multispecific engager is a bispecific engager.
- the bispecific engager comprises a CD16 binding domain and a CD30 binding domain.
- the CD 16 binding domain comprises a light chain variable domain (VL_CD16A) comprising a light chain complementarity determining region 1 (CDRL1) comprising SEQ ID NO: 9, a light chain complementarity determining region 2 (CDRL2) comprising SEQ ID NO: 10; a light chain complementarity determining region 3 (CDRL3) comprising SEQ ID NO: 11, and a heavy chain variable domain (VH_CD16A) comprising a heavy chain complementarity determining region 1 (CDRH1 comprising SEQ ID NO: 6; a heavy chain complementarity determining region 2 (CDRH2) comprising SEQ ID NO: 7; and a heavy chain complementarity determining region 3 (CDRH3) comprising SEQ ID NO: 8.
- VL_CD16A comprising a light chain complementarity determining region 1 (CDRL1) comprising SEQ ID NO: 9, a light chain complementarity determining region 2 (CDRL2) comprising SEQ ID NO: 10; a light chain complementarity determining region 3 (CD
- the CD 16 binding domain comprises a light chain variable (VL) region comprising or consisting of an amino acid sequence having or having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 20 and a heavy chain variable (VH) region comprising or consisting of an amino acid sequence having or having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 19.
- VL light chain variable
- VH heavy chain variable
- the CD16 binding domain comprises a light chain variable (VL) region comprising or consisting of SEQ ID NO: 20 and a heavy chain variable (VH) region comprising or consisting of SEQ ID NO: 19.
- VL light chain variable
- VH heavy chain variable
- the CD30 binding domain comprises: a light chain variable domain (VL_CD30) comprising a light chain complementarity determining region 1 (CDRL1) comprising SEQ ID NO: 15, a light chain complementarity determining region 2 (CDRL2) comprising SEQ ID NO: 16, a light chain complementarity determining region 3 (CDRL3) comprising SEQ ID NO: 17; and a heavy chain variable domain (VH_CD30) comprising a heavy chain complementarity determining region 1 (CDRH1) comprising SEQ ID NO: 12; a heavy chain complementarity determining region 2 (CDRH2) comprising SEQ ID
- CDRH3 heavy chain complementarity determining region 3
- the CD30 binding domain comprises a light chain variable (VL) region compri sing or consi sting of an amino acid sequence having or having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 22 and a heavy chain variable (VH) region comprising or consi sting of an amino acid sequence having or having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 21.
- VL light chain variable
- VH heavy chain variable
- the CD30 binding domain comprises: a light chain variable (VL.) region comprising SEQ ID NO: 22 and a heavy chain variable (VH) region comprising SEQ ID NO: 21 .
- VL. light chain variable
- VH heavy chain variable
- the multispecific engager is a tetravalent homodimer.
- the tetravalent homodimer comprises a first and second polypeptide monomer, each comprising or consisting of, from the N-terminus to the C-terminus: a CD16A heavy chain variable domain (VH_CD16A) - a first linker (L 1) - a CD30 light chain variable domain (VL_CD30) - a second linker (L2) - a CD30 heavy chain variable domain (VH_CD30) - a third linker (L3) - and a CD16 light chain variable domain (VL_CD16).
- the first and second polypeptides dimerize from head to tail through non-covalent interactions of the domains in the Ig heavy (VH) and light (VL) variable chains.
- the multispecific engager is a tetravalent homodimer.
- the tetravalent homodimer comprises a first and second polypeptide monomer, each comprising or consisting of, from the N-terminus to the C-terminus: a CD30 heavy chain variable domain (VH_CD30) - a first linker (L 1) - a CD16A light chain variable domain (VL_CD16A) - a second linker (L2) - a CD16A heavy chain variable domain (VH_CD16A) - a third linker (L3) - and a CD16 light chain variable domain (VL_CD30).
- the first and second polypeptides dimerize from head to tail through non- covalent interactions of the domains in the Ig heavy (VH) and light (VL) variable chains.
- VH_CD 16 comprises a heavy chain complementarity determining region 1 (CDR.H1 comprising SEQ ID NO: 6, a heavy chain complementarity determining region 2 (CDRH2) comprising SEQ ID NO: 7; and a heavy chain complementarity determining region 3 (CDRH3) comprising SEQ ID NO: 8.
- VH_CD16 comprises or consists of SEQ ID NO: 19.
- VL_CD16 comprises a light chain complementarity determining region 1 (CDRL1) comprising SEQ ID NO: 9, a light chain complementarity determining region 2 (CDR.L2) comprising SEQ ID NO: 10; and a light chain complementarity determining region 3 (CDRL3) comprising SEQ ID NO: 11.
- VL_CD16A comprises or consists of SEQ ID NO: 20,
- VH_CD30 comprises a heavy chain complementarity determining region 1 (CDRH1 comprising SEQ ID NO: 12; a heavy chain complementarity determining region 2 (CDRH2) comprising SEQ ID NO: 13; and a heavy chain complementarity determining region 3 (CDRH3) comprising SEQ ID NO: 14.
- VH_CD30 comprises or consists of SEQ ID NO: 21.
- VL_CD30 comprises a light chain complementarity determining region 1 (CDR.L1) comprising SEQ ID NO: 15; a light chain complementarity determining region 2 (CDRL2) comprising SEQ ID NO: 16; and a light chain complementarity determining region 3 (CDRL3) comprising SEQ ID NO: 17.
- VL_CD16A comprises or consists of SEQ ID NO: 22.
- L 1 comprises or consists of SEQ ID NO: 26.
- L2 comprises or consists of SEQ ID NO: 27.
- L3 comprises or consists of SEQ ID NO: 28.
- the first and second polymeric monomers each comprise or consists of SEQ ID NO: 18.
- the multispecific engager comprises a tag, e.g., a histidine tag, e.g., a hexa-histidine tag (SEQ ID NO: 25).
- the multispecific engager is AFM13. See, e.g., Wu et al., “AFF13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy,” J.
- NK cell receptor defines proteins and protein complexes on the surface of NK cells.
- the term defines cell surface molecules, which are characteristic to NK cells, but are not necessary exclusively expressed on the surface of NK cells but also on other cells such as macrophages or T cells.
- Examples for NK cell receptors comprise, but are not limited to Fc ⁇ RIII (CD 16a, CD 16b), NKp46 and NKG2D.
- CD 16a refers to the activating receptor CD16a, also known as Fc ⁇ RIII A, expressed on the cell surface of NK cells.
- CDl oa is an activating receptor triggering the cytotoxic activity of NK cells.
- the affinity of antibodies for CD 16a directly correlates with their ability to trigger NK cell activation, thus higher affinity towards CD 16a reduces the antibody dose required for activation.
- the antigen-binding site of the antigen-binding protein binds to CDI6a, but not to CD16b.
- an antigen-binding site comprising heavy (VH) and light (VL) chain variable domains binding to CD16a, but not binding to CD16B, may be provided by an antigen binding site which specifically binds to an epitope of CD 16a which comprises amino acid residues of the C-terminal sequence SFFPPGYQ (SEQ ID NO: 23) and/or residues G130 and/or Y141 of CD16a (SEQ ID NO: 24) which are not present in CD16b.
- CD16b refers to receptor CD16b, also known as Fc ⁇ RIIIB, expressed on neutrophils and eosinophils.
- the receptor is glycosylphosphatidyl inositol (GPI) anchored and is understood to not trigger any kind of cytotoxic activity of CD 16b positives immune cells.
- GPI glycosylphosphatidyl inositol
- target cell surface antigen refers to an antigenic structure expressed by a cell and which is present at the cell surface such that it is accessible for an antibody construct as described herein.
- target cell surface antigen to which the multi specific antibody constructs described herein binds to is CD30.
- CD30 also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker.
- the antibody constructs as defined in the context of the invention are (at least) bispecific, they do not occur naturally and they are markedly different from naturally occurring products.
- a "multispecific" antibody construct or immunoglobulin is hence an artificial hybrid antibody or immunoglobulin having at least two distinct binding sides with different specificities.
- Multispecific antibody constructs can be produced by a variety of methods including fusion of hybridomas or linking of Fab’ fragments. See, e.g., Songsivilai & Lachmann, Clin. Exp. Immunol . 79:315- 321 (1990).
- the at least two binding domains and the variable domains (VH / VL) of the antibody construct of the present disclosure may or may not comprise peptide linkers (spacer or connector peptides).
- the term "peptide linker" comprises an amino acid sequence by which the amino acid sequences of one (variable and/or binding) domain and another (variable and/or binding) domain of the antibody construct defined herein are linked with each other.
- the peptide linkers can also be used to fuse the third domain to the other domains or an Fc part of the antibody construct defined herein.
- such peptide linker does not comprise any polymerization activity.
- binding domain characterizes a domain which (specifically) binds to/interacts with/recognizes a given target epitope or a given target side on the target molecules (antigens), e.g. a NK cell receptor antigen, e.g. CD 16, and the target cell surface antigen CD30, respectively.
- a NK cell receptor antigen e.g. CD 16
- CD30 the target cell surface antigen CD30
- variable heavy chain (VH) and/or variable light chain (VL) domains of an antibody or fragment thereof are drawn from the variable heavy chain (VH) and/or variable light chain (VL) domains of an antibody or fragment thereof.
- the first binding domain is characterized by the presence of three light chain CDRs (i.e. CDR1, CDR2 and CDF3 of the VL region) and/or three heavy chain CDRs (i.e. CDR1, CDR2 and CDR3 of the VH region).
- the second binding domain preferably also comprises the minimum structural requirements of an antibody which allow for the target binding. More preferably, the second binding domain comprises at least three light chain CDRs (i.e.
- the first, and/or second binding domain is produced by or obtainable by phage-display or library screening methods rather than by grafting CDR sequences from a pre-existing (monoclonal) antibody into a scaffold.
- binding domains are in the form of one or more polypeptides.
- polypeptides may include proteinaceous parts and non-proteinaceous parts (e.g. chemical linkers or chemical cross-linking agents such as glutaraldehyde).
- Proteins including fragments thereof, preferably biologically active fragments, and peptides, usually having less than 30 amino acids) comprise two or more amino acids coupled to each other via a covalent peptide bond (resulting in a chain of amino acids).
- polypeptide describes a group of molecules, which usually consist of more than 30 amino acids. Polypeptides may further form multimers such as dimers, trimers and higher oligomers, i.e., consisting of more than one polypeptide molecule. Polypeptide molecules forming such dimers, trimers etc. may be identical or non-identical. The corresponding higher order structures of such multimers are, consequently, termed homo- or heterodimers, homo- or heterotrimers etc.
- An example for a heteromultimer is an antibody molecule, which, in its naturally occurring form, consists of two identical light polypeptide chains and two identical heavy polypeptide chains.
- peptide also refer to naturally modified peptides/ polypeptides / proteins wherein the modification is affected e.g. by post-translational modifications like glycosylation, acetylation, phosphorylation and the like.
- a “peptide”, “polypeptide” or “protein” when referred to herein may also be chemically modified such as pegylated. Such modifications are well known in the art and described herein below.
- the binding domain which binds to the NK cell receptor antigen, e.g. CD 16 and/or the binding domain which binds to the target cell surface antigen CD30 is/are human, humanized or murine derived chimeric binding domains.
- Antibodies and antibody constructs comprising at least one human binding domain avoid some of the problems associated with antibodies or antibody constructs that possess non-human such as rodent (e.g. murine, rat, hamster or rabbit) variable and/or constant regions. The presence of such rodent derived proteins can lead to the rapid clearance of the antibodies or antibody constructs or can lead to the generation of an immune response against the antibody or antibody construct by a patient.
- rodent derived antibodies or antibody constructs human or fully human antibodies/ antibody constructs can be generated through the introduction of human antibody function into a rodent so that the rodent produces fully human antibodies.
- this antigen-binding site for CD16A does not bind to CD16B and binds to the known CD16A allotypes F158 and V158 with similar affinity.
- Two allelic single nucleotide polymorphisms have been identified in human CD16A altering the amino acid in position 158, which is important for interaction with the hinge region of IgG.
- allelic frequencies of the homozygous 158 F/F and the heterozygous 158 V/F alleles are similar within the Caucasian population, ranging between 35 and 52% or 38 and 50%, respectively, whereas the homozygous 158 V/V allele is only found in 10-15% (Lopez-Escamez JA et al BMC Med Genet 2011; 12: 2).
- Activation of NK-cells by this anti-CD16A domain in all patients due to the similar affinity is therefore advantageous.
- Further CD16A antigen-binding sites comprising heavy and light variable chain domains that bind to CD 16A, but not to CD16B are described in WO 2006/125668.
- the heavy and light chain domains incorporate immunologically active homologues or variants of the CDR or framework sequences described herein.
- a CDR variant sequence is modified to change non-critical residues or residues in non-critical regions.
- Amino acids that are not critical can be identified by known methods, such as affinity maturation, CDR walking mutagenesis, site-directed mutagenesis, crystallization, nuclear magnetic resonance, photoaffinity labeling, or alanine- scanning mutagenesis.
- compositions comprising the natural killer cells described herein.
- compositions typically include a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
- the pharmaceutical composition comprises: a) natural killer cell(s) described herein; and b) a cryopreservation composition.
- the pharmaceutical composition comprises: a) a cryopreservation composition described herein; and b) therapeutic cell(s).
- the therapeutic cell(s) are animal cell(s). In some embodiments, the therapeutic cell(s) are human cell(s).
- the therapeutic cell(s) are immune cell(s).
- the immune cell(s) are selected from basophils, eosinophils, neutrophils, mast cells, monocytes, macrophages, neutrophils, dendritic cells, natural killer cells, B cells, T cells, and combinations thereof.
- the immune cell(s) are natural killer (NK) cells.
- the natural killer cell(s) are expanded and stimulated by a method described herein.
- the pharmaceutical composition further comprises: c) a buffer solution.
- Suitable buffer solutions are described herein, e.g., as for cryopreservation compositions.
- the pharmaceutical composition comprises from or from about 1x10 7 to or to about 1x10 9 cells/mL. In some embodiments, the pharmaceutical composition comprises 1x10 8 cells/mL. In some embodiments, the pharmaceutical composition comprises about 1x10 8 cells/mL.
- the pharmaceutical composition further comprises a multispecific engager, e.g., a multispecific engager described herein.
- compositions are typically formulated to be compatible with its intended route of administration.
- routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.
- Methods of formulating suitable pharmaceutical compositions are known in the art, see, e.g., Remington: The Science and Practice of Pharmacy, 21st ed., 2005; and the books in the series Drugs and the Pharmaceutical Sciences: a Series of Textbooks and Monographs (Dekker, NY).
- solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- compositions suitable for injectable use can include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS).
- the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition.
- Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum drying and freeze-drying, which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- NK cells described herein find use for treating cancer or other proliferative disorders.
- a disorder associated with a cancer e.g., a CD30+ cancer
- methods of treating a patient suffering from a disorder comprising administering the NK. cells, e.g., the NK cells described herein, and a CD30 targeting multispecific engager, e.g., a multispecific engager described herein.
- Also provided herein are methods for inducing the immune system in a subject in need thereof comprising administering the NK cells, e.g., the NK cells described herein, and a CD30 targeting multispecific engager, e.g., a multispecific engager described herein.
- the methods described herein include methods for the treatment of disorders associated with abnormal apoptotic or differentiative processes, e.g., cellular proliferative disorders or cellular differentiative disorders, e.g., cancer, including both solid tumors and hematopoietic cancers.
- the methods include administering a therapeutically effective amount of a treatment as described herein, to a subject, who is in need of, or who has been determined to be in need of, such treatment.
- the methods include administering a therapeutically effective amount of a treatment comprising an NK cells, e.g., NK cells described herein, and a CD30 targeting multi specific engager, e.g., a multispecific engager described herein..
- treatment refers to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disorder associated with abnormal apoptotic or differentiative processes.
- a treatment can result in a reduction in tumor size or growth rate.
- Administration of a therapeutically effective amount of a compound described herein for the treatment of a condition associated with abnormal apoptotic or differentiative processes wall result in a reduction in tumor size or decreased growth rate, a reduction in risk or frequency of reoccurrence, a delay in reoccurrence, a reduction in metastasis, increased survival, and/or decreased morbidity and mortality, among other things.
- treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.
- the terms “inhibition”, as it relates to cancer and/or cancer cell proliferation, refer to the inhibition of the growth, division, maturation or viability of cancer cells, and/or causing the death of cancer cells, individually or in aggregate with other cancer cells, by cytotoxicity, nutrient depletion, or the induction of apoptosis.
- “delaying” development of a disease or disorder, or one or more symptoms thereof means to defer, hinder, slow, retard, stabilize and/or postpone development of the disease, disorder, or symptom thereof. This delay can be of varying lengths of time, depending on the history of the disease and/or subject being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the subject does not develop the disease, disorder, or symptom thereof.
- a method that “delays” development of cancer is a method that reduces the probability of disease development in a given time frame and/or reduces extent of the disease in a given time frame, when compared to not using the method. Such comparisons may be based on clinical studies, using a statistically significant number of subjects.
- prevention refers to a regimen that protects against the onset of the disease or disorder such that the clinical symptoms of the disease do not develop.
- prevention relates to administration of a therapy (e.g., administration of a therapeutic substance) to a subject before signs of the disease are detectable in the subject and/or before a certain stage of the disease (e.g., administration of a therapeutic substance to a subject with a cancer that has not yet metastasized).
- the subject may be an individual at risk of developing the disease or disorder, or at risk of disease progression, e.g., cancer metastasis. Such as an individual who has one or more risk factors known to be associated with development or onset of the disease or disorder.
- an individual may have mutations associated with the development or progression of a cancer. Further, it is understood that prevention may not result in complete protection against onset of the disease or disorder. In some instances, prevention includes reducing the risk of developing the disease or disorder. The reduction of the risk may not result in complete elimination of the risk of developing the disease or disorder.
- An “increased” or “enhanced” amount refers to an increase that is 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, or 50 or more times (e.g., 100, 500, 1000 times) (including all integers and decimal points in between and above 1, e.g., 2.1, 2.2, 2.3, 2.4, etc.) an amount or level described herein.
- It may also include an increase of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, at least 200%, at least 500%, or at least 1000% of an amount or level described herein.
- a “decreased” or “reduced” or “lesser” amount refers to a decrease that is about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6
- an amount or level described herein may also include a decrease of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, at least 100%, at least 150%, at least 200%, at least 500%, or at least 1000% of an amount or level described herein.
- Examples of cellular proliferative and/or different! ative disorders include cancer, e.g., carcinoma, sarcoma, metastatic disorders or hematopoietic neoplastic disorders, e.g., leukemias.
- a metastatic tumor can arise from a multitude of primary tumor types, including but not limited to those of prostate, colon, lung, breast and liver origin.
- cancer refers to cells having the capacity for autonomous growth, i.e., an abnormal state or condition characterized by rapidly proliferating cell growth.
- hyperproliferative and neoplastic disease states may be categorized as pathologic, i.e., characterizing or constituting a disease state, or may be categorized as non-pathologic, i.e., a deviation from normal but not associated with a disease state.
- Pathologic hyperproliferative cells occur in disease states characterized by malignant tumor growth.
- non-pathologic hyperproliferative cells include proliferation of cells associated with wound repair.
- cancer or “neoplasms” include malignancies of the various organ systems, such as affecting lung, breast, thyroid, lymphoid, gastrointestinal, and genito-urinary tract, as well as adenocarcinomas which include malignancies such as most colon cancers, renal- cell carcinoma, prostate cancer and/or testicular tumors, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus.
- carcinoma is art recognized and refers to malignancies of epithelial or endocrine tissues including respiratory system carcinomas, gastrointestinal system carcinomas, genitourinary’ system carcinomas, testicular carcinomas, breast carcinomas, prostatic carcinomas, endocrine system carcinomas, and melanomas.
- the disease is renal carcinoma or melanoma.
- Exemplary carcinomas include those forming from tissue of the cervix, lung, prostate, breast, head and neck, colon and ovary.
- carcinosarcomas e.g., which include malignant tumors composed of carcinomatous and sarcomatous tissues.
- An “adenocarcinoma” refers to a carcinoma derived from glandular tissue or in which the tumor cells form recognizable glandular structures.
- sarcoma is art recognized and refers to malignant tumors of mesenchymal derivation.
- hematopoietic neoplastic disorders includes diseases involving hyperplastic/neoplastic cells of hematopoietic origin, e.g., arising from myeloid, lymphoid or erythroid lineages, or precursor cells thereof.
- the diseases arise from poorly differentiated acute leukemias, e.g., erythroblastic leukemia and acute megakaryoblastic leukemia.
- myeloid disorders include, but are not limited to, acute promyeloid leukemia (APML), acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CAIL) (reviewed in Vaickus, L. (1991) Crit Rev. in Oncol. /Hem otol. 11 :267-97); lymphoid malignancies include, but are not limited to acute lymphoblastic leukemia (ALL) which includes B-lineage ALL and T-lineage ALL, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HLL) and Waldenstrom's macroglobulinemia (WAI).
- ALL acute lymphoblastic leukemia
- CLL chronic lymphocytic leukemia
- PLL prolymphocytic leukemia
- HLL hairy cell leukemia
- WAI Waldenstrom's macroglobulinemia
- malignant lymphomas include, but are not limited to non-Hodgkin lymphoma and variants thereof, peripheral T cell lymphomas, adult T cell leukemia/lymphoma (ATL), cutaneous T-cell lymphoma (CTCL), large granular lymphocytic leukemia (LGF), Hodgkin's disease and Reed-Sternberg disease.
- the cancer is selected from the group consisting of: acute lymphoblastic leukemia (ALL), acute myeloid leukemia (ANIL), adrenocortical carcinoma, Kaposi sarcoma, AIDS-related lymphoma, primary CNS lymphoma, anal cancer, appendix cancer, astrocytoma, typical teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain tumor, breast cancer, bronchial tumor, Burkitt lymphoma, carcinoid, cardiac tumors, medulloblastoma, germ cell tumor, primary CNS lymphoma, cervical cancer, cholangiocarcinoma, chordoma, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), chronic myeloproliferative neoplasms, colorectal cancer, craniopharyngioma, cutaneous T-cell lympho
- ALL acute lymphoblastic
- the cancer is a solid tumor.
- the cancer is metastatic.
- the cancer is a CD30+ cancer.
- the CD30+ cancer is a lymphoma.
- the lymphoma is selected from the group consisting of classic Hodgkin lymphoma (CHL), anaplastic large cell lymphoma (ALCL), grey zone lymphoma (GZL), Epstein-Barr virus- positive diffuse large B-cell lymphoma (EBV+ DLBCL), and combinations thereof.
- the methods of treatment provided herein may be used to treat a subject (e.g., human, monkey, dog, cat, mouse) who has been diagnosed with or is suspected of having a cellular proliferative and/or differentiative disorder, e.g., a cancer.
- a subject e.g., human, monkey, dog, cat, mouse
- the subject is a mammal.
- the subject is a human.
- a subject refers to a mammal, including, for example, a human.
- the mammal is selected from the group consisting of an armadillo, an ass, a bat, a bear, a beaver, a cat, a chimpanzee, a cow, a coyote, a deer, a dog, a dolphin, an elephant, a fox, a panda, a gibbon, a giraffe, a goat, a gopher, a hedgehog, a hippopotamus, a horse, a humpback whale, a jaguar, a kangaroo, a koala, a leopard, a lion, a llama, a lynx, a mole, a monkey, a mouse, a narwhal, an orangutan, an orca, an otter, an ox, a pig, a polar bear, a porcupine, a puma,
- the mammal is a human.
- the subject e.g., the human subject
- the subject can be a child, e.g., from or from about 0 to or to about 14 years in age.
- the subject can be a youth, e.g., from or from about 15 to or to about 24 years in age.
- the subject can be an adult, e.g., from or from about 25 to or to about 64 years in age.
- the subject can be a senior, e.g, 65+ years in age.
- the subject may be a human who exhibits one or more symptoms associated with a cellular proliferative and/or differentiative disorder, e.g., a cancer, e.g., a tumor.
- the cancer stage includes but is not limited to early, advanced, locally advanced, remission, refractory, reoccurred after remission and progressive.
- the subject is at an early stage of a cancer.
- the subject is at an advanced stage of cancer.
- the subject has a stage I, stage II, stage III or stage IV cancer.
- the methods of treatment described herein can promote reduction or retraction of a tumor, decrease or inhibit tumor growth or cancer cell proliferation, and/or induce, increase or promote tumor cell killing.
- the subject is in cancer remission.
- the methods of treatment described herein can prevent or delay metastasis or recurrence of cancer.
- the subject is at risk, or genetically or otherwise predisposed (e.g., risk factor), to developing a cellular proliferative and/or differentiative disorder, e.g., a cancer, that has or has not been diagnosed.
- a cellular proliferative and/or differentiative disorder e.g., a cancer
- an “at risk” individual is an individual who is at risk of developing a condition to be treated, e.g., a cellular proliferative and/or differentiative disorder, e.g., a cancer.
- a condition to be treated e.g., a cellular proliferative and/or differentiative disorder, e.g., a cancer.
- an “at risk” subject may or may not have detectable disease, and may or may not have displayed detectable disease prior to the treatment methods described herein.
- “At risk” denotes that an individual has one or more so-called risk factors, which are measurable parameters that correlate with development of a disease or condition and are known in the art.
- an at risk subject may have one or more risk factors, which are measurable parameters that correlate with development of cancer.
- risk factors may include, for example, age, sex, race, diet, history of previous disease, presence of precursor disease, genetic (e.g., hereditary) considerations, and environmental exposure.
- the subjects at risk for cancer include, for example, those having relatives who have experienced the disease, and those whose risk is determined by analysis of genetic or biochemical markers.
- the subject may be undergoing one or more standard therapies, such as chemotherapy, radiotherapy, immunotherapy, surgery, or combination thereof Accordingly, one or more kinase inhibitors may be administered before, during, or after administration of chemotherapy, radiotherapy, immunotherapy, surgery or combination thereof.
- the subject may be a human who is (i) substantially refractor ⁇ ' to at least one chemotherapy treatment, or (ii) is in relapse after treatment with chemotherapy, or both (i) and (ii).
- the subject is refractory to at least two, at least three, or at least four chemotherapy treatments (including standard or experimental chemotherapies).
- the patient is diagnosed with or has been diagnosed with CD30+ cancer
- the patient is diagnosed with or has been diagnosed with a CD30+ cancer by immunohistochemical staining of a biopsy or surgical sample of the cancer. In some embodiments, the patient is diagnosed with or has been diagnosed with a CD30+ cancer by chromogenic in situ hybridization. In some embodiments, the patient is diagnosed with or has been diagnosed with a CD30+ cancer by fluorescent in situ hybridization of a biopsy or surgical sample of the cancer. In some embodiments, the patient is diagnosed with or has been diagnosed with a CD30+ cancer by genetic analysis.
- the patient is refractory to or has a recurrence after treatment with a CD30 inhibitor.
- the patient is refractory to or has a recurrence after treatment with a chemotherapy drug.
- the chemotherapy drug is selected from the group consisting of cisplatin, docetaxel, carboplatin, gemcitabine, cisplatin, pemetrexed, or combinations thereof
- the patient is refractory to or has a recurrence after treatment with a tyrosine kinase inhibitor.
- the tyrosine kinase inhibitor is selected from the group consisting of gefitinib, erlontinib, afatinib, osimertinib, and combinations thereof.
- the patient is lymphodepleted before treatment.
- the lymphodepleting chemotherapy regimen comprises administering to the patient doses of cyclophosphamide (between 200 mg/m 2 /day and 2000 mg/m 2 /day) and doses of fludarabine (between 20 mg/m 2 /day and 900 mg/m 2 /day).
- lymphodepletion comprises administration of or of about 250 to about 500 mg/m 2 of cyclophosphamide, e.g., from or from about 250 to or to about 500, 250, 400, 500, about 250, about 400, or about 500 mg/m 2 of cyclophosphamide.
- lymphodepletion comprises administration of or of about 20 mg/m 2 /day to or to about 40 mg/m 2 /day fludarabine, e.g., 30 or about 30 mg/m 2 /day.
- lymphodepletion comprises administration of both cyclophosmamide and fludarabine.
- the patient is lymphodepleted by intravenous administration of cyclophosphamide (250 mg/m 2 /day) and fludarabine (30 mg/m7day).
- the patient is lymphodepleted by intravenous administration of cyclophosphamide (500 mg/m 2 /day) and fludarabine (30 mg/m 2 /day).
- the lymphodepletion occurs no more than 5 days prior to the first dose of NK cells. In some embodiments, the lymphodepletion occurs no more than 7 days prior to the first dose of NK cells.
- lymphodepletion occurs daily for 3 consecutive days, starting 5 days before the first dose of NK cells (i.e., from Day -5 through Day -3).
- the lymphodepletion occurs on day -5, day -4 and day -3.
- the NK cells are administered as part of a pharmaceutical composition, e.g., a pharmaceutical composition described herein.
- the NK cells e.g., the NK cells described herein are administered at or at about 1 x 10 8 to or to about 8 x 10 9 NK cells per dose. In some embodiments, the NK cells are administered at or at about 1 x 10 8 , at or at about 1 x 10 9 , at or at about 4 x 10 9 , or at or at about 8 x 10 9 NK cells per dose.
- the NK cells are administered weekly. In some embodiments, the NK cells are administered for or for about weeks. In some embodiments, the NK cells are administered weekly for or for about 8 weeks.
- the NK cells are cryopreserved in an infusion-ready media, e.g., a cryopreservation composition suitable for intravenous administration, e.g., as described herein.
- the NK cells are cryopreserved in vials containing from or from about 1 x 10 8 to or to about 8 x 10 9 cells per vial.
- the NK cells are cryopreserved in vials containing a single dose.
- the cells are thawed, e.g., in a 37°C water bath, prior to administration.
- the thawed vial(s) of NK cells are aseptically transferred to a single administration vessel, e.g., administration bag using, e.g., a vial adapter and a sterile syringe.
- the NK cells can be administered to the patient from the vessel through a Y-type blood/solution set filter as an IV infusion, by gravity.
- the NK cells are administered as soon as practical, preferably less than 90 minutes, e.g., less than 80, 70, 60, 50, 40, 30, 20, or 10 minutes after thawing. In some embodiments, the NK cells are administered within 30 minutes of thawing.
- the pharmaceutical composition is administered intravenously via syringe.
- 1 mL, 4 mL, or 10 mL of drug product is administered to the patient intravenously via syringe.
- the NK cell(s) described herein e.g., the pharmaceutical compositions comprising NK cell(s) described herein, are administered in combination with a multispecific engager, e.g., a multispecific engager described herein, e.g., an CD30-targeting multispecific engager.
- a multispecific engager is administered together with the NK cells as part of a pharmaceutical composition.
- a multispecific engager is administered separately from the NK cells, e.g., as part of a separate pharm aceuti cal composition .
- the multispecific engager is administered before the NK cells. In some embodiments, the multispecific engager is administered after the NK cells.
- the NK cells are administered the day after the multispecific engager is administered.
- the NK cells are administered at each administration, while the multispecific engager is administered at a subset of the administrations. For example, in some embodiments, the NK cells are administered once a week and the multispecific engager is administered once a month. [0294] In some embodiments, a dose of multi specific engager is given prior to the first dose of cells. In some embodiments, a debulking dose of the multispecific engager is given prior to the first dose of cells.
- an “effective amount” is an amount sufficient to effect beneficial or desired results.
- a therapeutic amount is one that achieves the desired therapeutic effect. This amount can be the same or different from a prophylactically effective amount, which is an amount necessary to prevent onset of disease or disease symptoms.
- An effective amount can be administered in one or more administrations, applications or dosages.
- a therapeutically effective amount of a therapeutic compound i.e., an effective dosage
- the compositions can be administered one from one or more times per day to one or more times per week; including once every other day.
- treatment of a subject with a therapeutically effective amount of the therapeutic compounds described herein can include a si ngle treatment or a series of treatments.
- Dosage, toxicity and therapeutic efficacy of the therapeutic compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
- Compounds which exhibit high therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
- the data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
- the dosage of such compounds may be within a range of circulating concentrations that include the ED50 with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture.
- IC50 i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms
- levels in plasma may be measured, for example, by high performance liquid chromatography.
- the molecule(s) or components thereof described herein, the fusion protein(s) or components thereof described herein, or the NK cell genotypes described herein are at least 80%, e.g., at least 85%, 90%, 95%, 98%, or 100% identical to the amino acid sequence of an exemplary sequence (e.g., as provided herein), e.g., have differences at up to 1%, 2%, 5%, 10%, 15%, or 20% of the residues of the exemplary sequence replaced, e.g., with conservative mutations, e.g., including or in addition to the mutations described herein.
- the variant retains desired activity of the parent.
- the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non- homologous sequences can be disregarded for comparison purposes).
- the length of a reference sequence aligned for compari son purposes is at least 80% of the length of the reference sequence, and in some embodiments is at least 90% or 100%.
- the nucleotides at corresponding amino acid positions or nucleotide positions are then compared.
- nucleic acid “identity” is equivalent to nucleic acid "homology”
- percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
- Percent identity between a subject polypeptide or nucleic acid sequence (i.e. a query) and a second polypeptide or nucleic acid sequence (i.e. target) is determined in various ways that are within the skill in the art, for instance, using publicly available computer software such as Smith Waterman Alignment (Smith, T. F. and M. S.
- the length of compari son can be any length, up to and including full length of the target (e.g., 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100%).
- percent identity is relative to the full length of the query sequence.
- the comparison of sequences and determination of percent identity between two sequences can be accomplished using a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.
- Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.
- determining means determining if an element is present or not (for example, detection). These terms can include quantitative, qualitative or quantitative and qualitative determinations. Assessing can be relative or absolute. “Detecting the presence of” can include determining the amount of something present in addition to determining whether it is present or absent depending on the context.
- in vivo is used to describe an event that takes place in a subject’s body.
- ex vivo is used to describe an event that takes place outside of a subject’s body.
- An ex vivo assay is not performed on a subject. Rather, it is performed upon a sample separate from a subject.
- An example of an ex vivo assay performed on a sample is an “in vitro” assay.
- in vitro is used to describe an event that takes places contained in a container for holding laboratory reagent such that it is separated from the biological source from which the material is obtained.
- in vitro assays can encompass cell-based assays in which living or dead cells are employed.
- In vitro assays can also encompass a cell-free assay in which no intact cells are employed.
- the term “about” a number refers to that number plus or minus 10% of that number.
- the term “about” a range refers to that, range minus 10% of its lowest value and plus 10% of its greatest value.
- buffer solution refers to an aqueous solution consisting of a mixture of a weak acid and its conjugate base, or vice versa.
- cell culture medium refers to a mixture for growth and proliferation of cells in vitro, which contains essential elements for growth and proliferation of cells such as sugars, amino acids, various nutrients, inorganic substances, etc.
- a buffer solution is not. a cell culture medium.
- the term “bioreactor” refers to a culture apparatus capable of continuously controlling a series of conditions that affect cell culture, such as dissolved oxygen concentration, dissolved carbon dioxide concentration, pH, and temperature.
- vector refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked.
- the term includes the vector as a self- replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced.
- Some vectors are suitable for delivering the nucleic acid molecule(s) or polynucleotide(s) of the present application.
- Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as expression vectors.
- operably linked refers to two or more nucleic acid sequence or polypeptide elements that are usually physically linked and are in a functional relationship with each other.
- a promoter is operably linked to a coding sequence if the promoter is able to initiate or regulate the transcription or expression of a coding sequence, in which case, the coding sequence should be understood as being “under the control of” the promoter.
- host cell refers to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells.
- Host cells include “engineered cells,” “transformants,” and “transformed cells,” which include the primary engineered (e.g., transformed) cell and progeny derived therefrom without regard to the number of passages.
- Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.
- the host cells can be stably or transiently transfected with a polynucleotide encoding a fusion protein, as described herein.
- FIG. 1 A single unit of FDA-licensed, frozen cord blood that has a high affinity variant of the receptor CD 16 (the 158 V/V variant, see, e.g., Koene et al., “Fc ⁇ RIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcgammaRIIIa, Independently of the FcgammaRIIIa-48L/'R/H Phenotype,” Blood 90: 1109—14 (1997).) and the KIR-B genotype (KIR B allele of the KIR receptor family, see, e.g., Hsu et al., “The Killer Cell Immunoglobulin-Like Receptor (K IR ) Genomic Region: Gene-Order, Haplotypes and Allelic Polymorphism,” Immunological Review 190:40-52 (2002); and Pyo et al
- the cord blood unit was thawed and the freezing medium was removed via centrifugation.
- the cell preparation was then depleted of T cells using the QuadroMACS Cell Selection System (Miltenyi) and CD3 (T cell) MicroBeads.
- a population of nucleated cells (TNC) were labelled with the MicroBeads and separated using the QuadroMACS device and buffer.
- the remaining cells which were predominantly monocytes and NK cells, were washed and collected in antibiotic-free medium (CellgroSCGM).
- the cell preparation was then evaluated for total nucleated cell count, viability, and % CD3+ cells. As shown in FIG. 1 , the cord blood NK cells were CD3 depleted.
- the CD3- cell preparation was inoculated into a gas permeable cell expansion bag containing growth medium.
- the cells were co-cultured with replication incompetent engineered HuT-78 (eHUT-78) feeder cells to enhance expansion for master cell bank (MCB) production.
- the CellgroSCGM growth media was initially supplemented with anti-CD3 antibody (OKT3), human plasma, glutamine, and IL-2.
- the NK cells are optionally engineered, e.g., to introduce CARs into the NK cells, e.g., with a lentaviral vector, during one of the co-culturing steps.
- the cells were incubated as a static culture for 12-16 days at 37 C C in a 5% CO2 balanced air environment, with additional exchanges of media occurring every 2 to 4 days. After the culture has expanded more than 100-fold, the cultured cells were harvested and then suspended in freezing medium at 1.0 x 10 8 cells/mL and filled into 5 mF. cryobags. In this example, 80 bags or vials at 10 s cells per bag or vial were produced during the co-culture. The cryobags were frozen using a controlled rate freezer and stored in vapor phase liquid nitrogen (LN2) tanks below -150°C. These cryopreserved NK cells derived from the FDA-licensed cord blood unit served as the master cell bank (MCB).
- MBC2 vapor phase liquid nitrogen
- a bag of frozen cells from the MCB was thawed and the freezing medium was removed.
- the thawed cells were inoculated into a disposable culture bag and co-cultured with feeder cells, e.g., eHUT78 feeder cells to produce the drug product.
- the cells are cultured in a 50 L bioreactor to produce thousands of lots of the drug product per unit of cord blood (e.g., 4,000-8,000 cryovials at 10 9 cells/vial), which are mixed with a cryopreservation composition and frozen in a plurality of storage vessels such as cryovials.
- the drug product is an off-the-shelf infusion ready product that can be used for direct infusion.
- Each lot of the drug product can be used to infuse hundreds to thousands of patients (e.g., 100-1,000 patients, e.g. with a target dose of 4 x 10 9 cells).
- suitable feeder cells e.g., eHut-78 cells
- suitable feeder cells e.g., eHut-78 cells
- RPMI1640 Life Technologies
- FBS inactivated fetal bovine serum
- glutamine hyclone 2 mM
- cell viability was greater than or equal to 70% of the original number of cells (here, at least 1.0 x 10 8 viable cells/mL), and 85% or more of the cells expressed tmTNF- ⁇ , 85% or more of the cells expressed mb IL-21+, and 85% or more of the cells expressed
- suitable NK cells can be prepared as follows using HuT-78 cells transduced to express 4-1 BBL, membrane bound IL-21 and membrane bound TNF alpha (“eHut- 78P cells”) as feeder cells.
- the feeder cells are suspended in 1% (v/v) CellGro medium at 2.5* 10 6 cells/ml and are irradiated with 20,000 cGy in a gamma-ray irradiator.
- Seed cells e.g., CD3-depleted PBMC or CD3-depleted cord blood cells
- CellGro medium containing human plasma, glutamine, IL-2, andOKT-3 in in static culture at 37° C. The cells are split every 2-4 days.
- the NK cells are harvested by centrifugation and cryopreserved. Thawed NK are administered to patients in infusion medium consisting of: Phosphate Buffered Saline (PBS lx, FujiFilm Irvine), albumin (human) (OctaPharma albumin solution. Dextran 40 in Dextrose (Hospira Dextran 40 in Dextrose Injection, USP) and dimethyl sulfoxide (DMSO) (Avantor DMSL solution).
- Phosphate Buffered Saline PBS lx, FujiFilm Irvine
- albumin human
- Dextran 40 in Dextrose Hospira Dextran 40 in Dextrose Injection, USP
- DMSO dimethyl sulfoxide
- the seed cells are CD3-depleted cord blood cells.
- a cell fraction can be depleted of CD3 cells by immunomagnetic selection, for example, using a CliniMACS T cell depletion set ((LS Depletion set (162-01) Miltenyi Biotec).
- the cord blood seed cells are selected to express CD 16 having the V/V polymorphism at Fl 58 (Fc gamma RIIIa-158 V/V genotype) (Musolino et al. 2008 J Clin Oncol 26: 1789).
- the cord blood seed cells are KIR-B haplotype.
- AB-101 NK cells cord-blood derived and expanded NK cells selected for V/V and KIR-B (including 10% extra amount considering cell loss during centrifugation and formulation) were taken at harvest and transferred to the lab.
- Example 5 Antibody dependent cell-mediated cytotoxicity (ADCC) of AFM13 and AB-101 NK cells
- antibody-mediated target cell lysis by AB-101 NK cells in vitro was assessed by quantifying the release of calcein into cell culture supernatants from calcein- labeled Karpas-299 target cells after 4 hours.
- the assay was carried out with: 1) non- precomplexed (empty) AB- 101 cells that had previously been washed and cryopreserved alone (“non-preloaded” condition); 2) “non-preloaded” AB-101 cells as in condition 1 , but in combination with fresh (never frozen) AFM13 ("non-preloaded + fresh excess AFM13” condition), and 3) AB-101 cells preloaded with AFM13 (as described in Example 4), followed by removal of unbound AFM13 (i.e., washing) and subsequent cryopreservation.
- ciyopreserved AB-101 cells Prior to the assay, ciyopreserved AB-101 cells were swiftly thawed at 37°C and washed in PBS buffer supplemented with 2% FCS and 0.6% citrate-dextrose solution.
- Target cells were labeled with 10 ⁇ M calcein AM for 30 min in RPMI 1640 medium without FCS at 37°C. After gentle washing, calcein-labeled cells were resuspended in complete RPMI medium (i.e., RPMI 1640 medium supplemented with 10% h.i. FCS, 2 mM L glutamine, 100 U/mL penicillin G sodium, 100 ⁇ g/mL streptomycin sulfate) at a density of 1x10 5 /mL.
- complete RPMI medium i.e., RPMI 1640 medium supplemented with 10% h.i. FCS, 2 mM L glutamine, 100 U/mL penicillin G sodium, 100 ⁇ g/mL streptomycin sulfate
- Spontaneous calcein-release and maximal release were determined in quadruplicate on each plate. Spontaneous release was determined by incubation of target cells in the absence of effector NK cells and in the absence of AFMI3. Maximal release was achieved by adding Triton X 100 to a final concentration of 1% in the absence of effector cells and in the absence of antibodies. After centrifugation for 2 min at 200xg, microtiter plates were incubated for 4 h at 37°C in a humidified atmosphere with 5% CO2. Following incubation, 100 pL cell- free cell culture supernatant was harvested from each well after centrifugation for 5 min at 500xg and transferred to black flat-bottom 96-w'ell microtiter plates.
- Fluorescence counts of released calcein were measured at 520 nm using a multimode plate reader. Specific cell lysis was calculated according to the following formula: [fluorescence (sample) - fluorescence (spontaneous)] / [fluorescence (maximum) - fluorescence (spontaneous)] x 100% wherein “Fluorescence (spontaneous)” and “Fluorescence (maximum)” are defined as fluorescence in absence of effector cells and antibodies and fluorescence induced by the addition of Triton X100, respectively.
- ADCC activity of AB-101 cells in combination with AFM13 exhibited an ADCC response as strong or stronger than AB-101 alone, both when AFM13 was added fresh and when it was pre-loaded prior to cry opreservation.
- Exampie 6 Retention of bound AFM13 after crvopreservation by AFM13- preloaded cryopreserved AB-101 NK cells
- FACS buffer i.e., PBS supplemented with 2% FCS and 0.1% sodium azide
- FACS buffer i.e., PBS supplemented with 2% FCS and 0.1% sodium azide
- Cells were incubated with rat anti-AFM13 clone 7 antibody (5 ⁇ g/mL, Affimed GmbH) diluted in FACS buffer or FACS alone for 30 min in the dark at 4°C, followed by washing and subsequent incubation with goat anti-rat FITC (1/100, Dianova) for 30 min in the dark at 4°C.
- control empty and control preloaded AB-101 were first freshly incubated with AFM 13 (10 ⁇ g/mL) prior to the staining procedures described above.
- AFM13- preloaded AB-101 NK cells were incubated with mouse anti-human CD16 BV421 (clone 3G8, 1/100, Biolegend), with mouse anti-human CD56 BV785 (clone 5.1H11, 1/100, Biolegend) and analyzed compared to corresponding concentration-matched mouse isotype controls (ah from Biolegend).
- FIG. 7 left: MCB2, right: MCB1
- CD 16 expression is detected on preloaded cryopreserved AB- 101 cells after thawing. Filled histograms represent CD16 staining; open histograms represent isotype control antibody staining only. The detection of uniform high AFM13 binding relative to uniform high CD16 expression suggests saturated binding of CD16 by AFM13.
- Example 7 AFM 13 mediated NK fratricide detection
- NK-NK cell lysis i.e., NK fratricide
- NK fratricide potentially mediated by cross-linking of two CD16 molecules or of CD30 and CD16 (by AFM 13 ) on two adjacent NK cells
- Target empty or preloaded AB-101 NK cells were labelled with caicein as described in Example 5. 5xl0 4 target NK cells were then seeded in individual wells of a round- bottom 96-well microtiter plate and, if not mentioned otherwise, mixed with effector empty or preloaded AB-101 NK cells at 1 : 1 E:T ratio. If indicated, 10 ⁇ g/mL of AFM 13 were added to individual wells to a total volume of 200 ⁇ L/well in duplicates.
- Example 8 NK cell activation in response to target cells by AFM13- preloaded cryopreserved AB-101 NK cells
- NK cell activation To monitor NK cell activation, up-regulation of CD107a (marker for NK cell degranulation) and intracellular IFN-y expression were assessed in response to Karpas-299 target cell lines and AFM13. Preloading procedures and thawing after cry opreservation were performed as described in Example 5.
- FIG. 10 Flow cytometry staining was performed as described in Example 5.
- FIG. 10 FIG. 11, FIG. 12, and FIG. 13, AFM13 -preloaded cells and empty AB-101 cells supplemented with AFM13 exhibited degranulation and increased production of IFN-y, specifically in response to Karpas-299 target cells, while AFM 13 -preloaded AB-101 cells and empty AB-101 cells supplemented with AFM13 did not exhibit significant degranulation or IFN- ⁇ expression in the absence of target cells.
- Viability analysis of cryopreserved AF Ms-preloaded AB-101 was performed after thawing and after additional 24 hour culture. As shown in FIG. 14, viability of AB-101 cells was over 80% post-thawing, and over 60% 24 hours post-thawing.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne des compositions pharmaceutiques comprenant : (a) une cellule tueuse naturelle (cellule NK) comprenant un haplotype KIR-b et l'expression d'une molécule CD16 ; et (b) un anticorps bispécifique ou un fragment de liaison à l'antigène de celui-ci comprenant un premier domaine de liaison qui se lie spécifiquement au CD16 (FcyRIII) et un second domaine de liaison qui se lie spécifiquement à CD30, et des procédés les comprenant.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2021/058136 WO2023080895A1 (fr) | 2021-11-04 | 2021-11-04 | Traitement du cancer avec des cellules nk et des agents de mise en contact multispécifiques |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2021/058136 WO2023080895A1 (fr) | 2021-11-04 | 2021-11-04 | Traitement du cancer avec des cellules nk et des agents de mise en contact multispécifiques |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023080895A1 true WO2023080895A1 (fr) | 2023-05-11 |
Family
ID=86241656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/058136 WO2023080895A1 (fr) | 2021-11-04 | 2021-11-04 | Traitement du cancer avec des cellules nk et des agents de mise en contact multispécifiques |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023080895A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11970547B2 (en) | 2017-11-14 | 2024-04-30 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130011376A1 (en) * | 2009-12-29 | 2013-01-10 | Gamida Cell Ltd. | Methods for Enhancing Natural Killer Cell Proliferation and Activity |
US20180085456A1 (en) * | 2015-05-04 | 2018-03-29 | Affimed Gmbh | Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy |
US20180208668A1 (en) * | 2003-05-02 | 2018-07-26 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
US20180369411A1 (en) * | 2015-04-14 | 2018-12-27 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
US20200108096A1 (en) * | 2017-05-26 | 2020-04-09 | Green Cross Lab Cell Corporation | Method for culturing natural killer cell, using transformed t cell |
-
2021
- 2021-11-04 WO PCT/US2021/058136 patent/WO2023080895A1/fr unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180208668A1 (en) * | 2003-05-02 | 2018-07-26 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
US20130011376A1 (en) * | 2009-12-29 | 2013-01-10 | Gamida Cell Ltd. | Methods for Enhancing Natural Killer Cell Proliferation and Activity |
US20180369411A1 (en) * | 2015-04-14 | 2018-12-27 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
US20180085456A1 (en) * | 2015-05-04 | 2018-03-29 | Affimed Gmbh | Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy |
US20200108096A1 (en) * | 2017-05-26 | 2020-04-09 | Green Cross Lab Cell Corporation | Method for culturing natural killer cell, using transformed t cell |
Non-Patent Citations (1)
Title |
---|
HERNANDEZ ERIC G., PARTIDA-RODRIGUEZ OSWALDO, CAMORLINGA-PONCE MARGARITA, NIEVES-RAMIREZ MIRIAM, RAMOS-VEGA IRMA, TORRES JAVIER, P: "Genotype B of Killer Cell Immunoglobulin-Like Receptor is Related with Gastric Cancer Lesions", SCIENTIFIC REPORTS, vol. 8, no. 1, 1 January 2018 (2018-01-01), pages 1 - 9, XP093065541, DOI: 10.1038/s41598-018-24464-2 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11970547B2 (en) | 2017-11-14 | 2024-04-30 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240000840A1 (en) | Treatment of cancer with nk cells and a cd20 targeted antibody | |
US20240115704A1 (en) | Treatment of cancer with nk cells and a cd38-targeted antibody | |
US20240060046A1 (en) | Expanded and stimulated natural killer cells | |
EP4319768A1 (fr) | Récepteur antigénique chimérique comprenant un anticorps anti-her2 ou un fragment de liaison à l'antigène de celui-ci et cellules tueuses naturelles le comprenant | |
WO2023080895A1 (fr) | Traitement du cancer avec des cellules nk et des agents de mise en contact multispécifiques | |
AU2022380926A1 (en) | Treatment of cancer with nk cells and multispecific engagers | |
US20240197778A1 (en) | Treatment of cancer with nk cells and a her2 targeted antibody | |
US20240180962A1 (en) | Treatment of cancer with nk cells and a cd20 targeted antibody | |
EP4319794A2 (fr) | Récepteur d'antigène chimère comprenant un anticorps anti-cd19 ou un fragment de liaison à l'antigène de celui-ci et cellules tueuses naturelles le comprenant | |
KR20230167416A (ko) | 키메라 항원 수용체 및 il-15를 포함하는 융합 단백질 | |
AU2022253889A1 (en) | Treatment of cancer with nk cells and an egfr targeted antibody | |
US20210380942A1 (en) | Methods and compositions for the treatment of cancer and infectious diseases | |
KR20240107147A (ko) | Nk 세포 및 다중특이적 인게이저를 이용한 암의 치료 | |
WO2024040135A2 (fr) | Procédés d'administration de cellules tueuses naturelles comprenant un récepteur antigénique chimérique (car) anti-récepteur 2 du facteur de croissance épidermique humain (her2) | |
CN117545490A (zh) | 用nk细胞和her2靶向抗体治疗癌症 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21963459 Country of ref document: EP Kind code of ref document: A1 |